Binary cryptocytotoxic method of hybrid seed production
This application is a continuing application of PCT/CA91/00255 which is a continuing application of application Ser. No. 07/556,917, filed Jul. 20, 1990, now abandoned. 
    
    
     FIELD OF THE INVENTION 
     The invention relates to a process for the preparation of a seed of a plant and to the products produced by the process. The invention also relates to a method of producing F1 hybrid seed from a plant grown from such seed, a method of producing F2 hybrid seed using plants grown from the F1 hybrid seed, the products produced from these methods and their use. 
     BACKGROUND ART 
     Production of hybrid seed for commercial sale is a large industry. Hybrid plants grown from hybrid seed benefit from the heterotic effects of crossing two genetically distinct breeding lines with the result that the agronomic performance of the offspring is superior to both parents, typically in vigour, yield, and uniformity. The better performance of hybrid seed varieties compared to open-pollinated varieties makes the hybrid seed more attractive for farmers to plant and thereby commands a premium price in the market place. 
     Genic male sterility has been utilized in hybrid seed production. Various methods of genic male sterility production and hybrid seed production using male sterile plants are described by the present inventors in published Australian Patent Application Serial No. 611258 and in published PCT Application No. PCT/CA90/00037 by Paladin Hybrids. 
     Other male sterility systems are disclosed for example in PCT Application No. PCT/WO89/10396 by Plant Genetic Systems. 
     SUMMARY OF THE INVENTION 
     The present invention relates to a method for the preparation of a seed of a plant comprising crossing a male sterile plant and a second plant which is male fertile, and obtaining seed of said male sterile plant, said male sterile plant and said second plant being selected such that said seed has integrated into its genome a first recombinant DNA molecule comprising a first DNA sequence which encodes a first gene product and a first promoter which is capable of regulating the expression of said first DNA sequence, and a second recombinant DNA molecule comprising a second DNA sequence which encodes a second gene product and a second promoter which is capable of regulating the expression of said second DNA sequence, one of said first and said second recombinant DNA molecules originating from said male sterile plant and the other of said first and second recombinant molecules originating from said second plant and said first and second gene products cooperating to selectively interfere with the function and/or development of cells of a plant that are critical to pollen formation and/or function of a plant grown from said seed whereby said plant grown from said seed is substantially male sterile. 
     Preferably, the male sterile plant is obtained by exposing a plant carrying a male sterile trait to a sterility actuating agent. 
     Preferably, the first recombinant DNA molecule and second recombinant DNA molecule are located on opposite chromatids of the same chromosome pair and most preferably on opposite chromatids of the same chromosome pair at the same genetic locus such that segregation of the first and second recombinant DNA molecules occurs during meiosis and the chance of recombination of the first and second recombinant DNA molecules to the same chromatid during meiotic crossing over is substantially reduced. 
     Preferably, the first DNA sequence encodes a first gene product which is capable of rendering a non-toxic substance cytotoxic to a cell of a plant which is critical to pollen formation and/or function and said second DNA sequence encodes a second gene product which is said non-toxic substance or encodes a second gene product which is capable of converting a substance endogenous to a plant cell to said non-toxic substance. 
     In accordance with one embodiment of the invention, the male sterile plant has integrated into its genome a first recombinant DNA molecule comprising a first DNA sequence which encodes a first gene product which is capable of rendering a non-toxic substance cytotoxic to a cell of a plant which is critical to pollen formation and/or function and a first promoter which is capable of regulating the expression of said first DNA sequence, the male sterile plant being produced by exposing a plant having said first recombinant DNA molecule integrated into its genome to said non-toxic substance, and wherein the second plant has integrated into its genome a second recombinant DNA molecule comprising a second DNA sequence which encodes a second gene product which is capable of converting a substance endogenous to a plant cell to the non-toxic substance and a second promoter which is capable of regulating the expression of said second DNA sequence. Preferably, the first DNA sequence encodes indole acetamide hydrolase (IamH), the second DNA sequence encodes indole acetamide synthase (IamS) and the first and second promoters are pollen specific promoters. 
     In accordance with another embodiment of the invention, the male sterile plant has integrated into its genome a first DNA sequence which encodes a first gene product which is capable of rendering a non-toxic substance cytotoxic to a cell of a plant which is critical to pollen formation and/or function and a first promoter which is capable of regulating the expression of said first DNA sequence,and a second DNA sequence which encodes a second gene product which is said non-toxic substance or encodes a second gene product which is capable of converting a substance endogenous to a plant cell to said non-toxic substance and a second promoter which is capable of regulating the expression of said second DNA sequence, one of said first promoter and said second promoter being an inducible promoter which is capable of being activated by an inducer throughout pollen formation, and the other of said first promoter or said second promoter is a pollen specific promoter, the male sterile plant being produced by exposing a plant having said first DNA sequence and said first promoter and said second DNA sequence and said second promoter integrated into its genome to said inducer, and wherein the second plant has integrated into its genome a pollen specific promoter or a constitutive promoter and either of said first or said second DNA sequences which is regulated by the inducible promoter which is integrated into the genome of said male sterile plant. 
     In particular, the male sterile plant may have integrated into its genome a first DNA sequence which encodes a first gene product which is capable of rendering a non-toxic substance cytotoxic to a cell of a plant which is critical to pollen formation and/or function regulated by an inducible promoter which is capable of being activated by an inducer throughout pollen formation, and a second DNA sequence which encodes a second gene product which is said non-toxic substance or a second gene product which is capable of converting a substance endogenous to a plant cell to said non-toxic substance regulated by a pollen specific promoter, the male sterile plant being produced by exposing a plant having said first DNA sequence regulated by said inducible promoter and said second DNA sequence regulated by said pollen specific promoter integrated into its genome to said inducer, and wherein the second plant has integrated into its genome said first DNA sequence and a pollen specific promoter or a constitutive promoter. 
     Preferably, the first DNA sequence encodes IamH, the second DNA sequence encodes IamS. The first DNA sequence may also encode an enzyme which is capable of rendering a protoxin cytotoxic to cells of a plant that are critical to pollen formation and/or function, and the second DNA sequence may encode a protoxin. 
     The male sterile plant may have integrated into its genome a first DNA sequence which encodes a first gene product which is capable of rendering a non-toxic substance cytotoxic to a cell of a plant which is critical to pollen formation and/or function regulated by a pollen specific promoter, and a second DNA sequence which encodes a second gene product which is said non-toxic substance or a second gene product which is capable of converting a substance endogenous to a plant cell to said non-toxic substance regulated by an inducible promoter which is capable of being activated by an inducer throughout pollen formation, the male sterile plant being produced by exposing a plant having said first DNA sequence regulated by said pollen specific promoter and said second DNA sequence regulated by said inducer integrated into its genome to said inducer, and wherein the second plant has integrated into its genome said second DNA sequence and a pollen specific promoter or a constitutive promoter. Preferably, the first DNA sequence encodes IamH, and the second DNA sequence encodes IamS. The first DNA sequence may also encode an enzyme which is capable of rendering a protoxin cytotoxic to cells of a plant that are critical to pollen formation and/or function, and the second DNA sequence may encode a protoxin. 
     It will be appreciated that the male sterile plants containing the first and second DNA sequences may have these DNA sequences located on the same recombinant DNA molecule or on different recombinant DNA molecules. 
     The invention also relates to a method for producing hybrid seed which comprises cross-pollinating a progeny male sterile plant grown from the seed obtained in accordance with the above described method of the invention, with a suitable male fertile plant which does not contain a first recombinant DNA molecule or second recombinant DNA molecule as hereinbefore described, and harvesting hybrid seed from the progeny male sterile plant. For ease of reference, this method of producing hybrid seed is hereinafter referred to as a binary cryptocytotoxic method of hybrid seed production. 
     A method is also provided for producing F2 plants by outcrossing F1 plants grown from the hybrid seed obtained from the progeny male sterile plant. The seed obtained from the F2 plants may be processed to obtain products such as edible oil, etc. Accordingly, the invention also relates to a method of using the seed of an F2 plant obtained in accordance with the methods of the present invention. 
     According to a preferred embodiment of the invention, the invention provides a method of producing seed of a male sterile plant, comprising: 
     (a) producing a male sterile plant line comprising 
     (i) introducing into the genome of one or more plant cells of a pollen-producing plant a first recombinant DNA molecule comprising a DNA sequence which encodes a gene product which when produced in a cell of a plant which is critical to pollen formation and/or function is capable of rendering a non-toxic substance cytotoxic to said cell, preferably said non-toxic substance is a chemical agent, most preferably 2-amino-4-methoxy butanoic acid, a non-toxic analog of glucuronic acid, naphthalene acetamide or indole acetamide, preferably said first recombinant DNA molecule comprises a pollen specific promoter and a selection marker gene which encodes a selection gene product which permits the selection of a plant having said first recombinant DNA molecule integrated into its genome; 
     (ii) selecting a plant cell into which the first recombinant DNA molecule is stably integrated; 
     (iii) regenerating from the selected plant cell a plant which carries the male sterile trait; 
     (iv) increasing the number of plants which carry the male sterile trait to produce a plant line having plants carrying the male sterile trait; and 
     (v) exposing said plant line to the non-toxic substance to render plants of said plant line male sterile; 
     (b) cross pollinating plants of the male sterile plant line obtained in (a) above with plants of a second plant line having a genome which stably incorporates a second recombinant DNA molecule comprising a second DNA sequence encoding a second gene product which is capable of converting a substance which is endogenous to cells of said second plant line, to said non-toxic substance; a second promoter capable of regulating the expression of said second DNA sequence, preferably a pollen-specific promoter; preferably said first and second recombinant DNA molecules are incorporated into homologous chromosome pairs, and wherein plants of said second plant line are not capable of rendering the non-toxic substance cytotoxic to cells of plants of said second line which are essential to pollen formation and/or function; and 
     (c) harvesting seed of plants of said male sterile line. 
     The above mentioned methods of the invention may be used to provide hybridization systems with the following advantages: 
     (a) Hybrid seed production is not labour intensive and can be achieved on a large scale with commercially acceptable costs; 
     (b) F1 hybrid seed is fully male fertile; 
     (c) the population of F2 plants produced by outcrossing F1 plants contain 12.5% male sterile plants, thereby discouraging seed saving or holdback for subsequent planting. 
    
    
     BRIEF DESCRIPTION OF THE DRAWINGS 
     FIGS. 1A and 1B illustrate an embodiment of the process of the invention using the IamH and IamS genes. 
     FIG. 2 illustrates the segregation patterns of the IamH and IamS genes in the F1 and F2 populations when the genes are on the same segregation unit. 
     FIG. 3 illustrates the procedure used for the isolation of the T-DNA gene 1 (the IamS: indole acetamide synthase gene) of the Agrobacterium tumefaciens Ti plasmid derivative pPCV 311 and the construction of a promoterless version of this gene. 
     FIGS. 4A and 4B illustrate the procedure used for the isolation of the T-DNA gene 2 (the IamH: indole acetamide hydrolase gene) of the Agrobacterium tumefaciens Ti plasmid derivative pPCV 311 and the construction of a promoterless version of this gene. 
     FIGS. 5A and 5B illustrate an embodiment of the invention using an IamH gene and an IamS gene. 
     FIG. 6 illustrates the segregation patterns of an IamH gene and an IamS gene in the F1 and F2 populations produced as illustrated in FIGS. 5A and 5B. 
     FIGS. 7A, 7B, 7C, 7D are schematic representations describing the production of vectors containing the promoter and promoter regions from clone L4 (SEQ. I.D. NOS. 3 and 4). 
     FIG. 7E shows a schematic representation of the promoter constructs produced as shown, schematically in FIGS. 7A to 7D. 
     FIG. 8 is a schematic representation describing the production of vectors containing the promoter regions of clone L10 (SEQ. NOS. 5 and 6). 
     FIG. 9 is a schematic representation describing the production of vectors containing the promoter regions of clone L19 (SEQ. NOS. 7 and 8). 
     FIG. 10 is a schematic diagram showing the preparation of pPAL0101 and pPALHP101. 
    
    
     DETAILED DESCRIPTION OF THE INVENTION 
     As hereinbefore mentioned the present invention relates to a method for the preparation of a seed of a plant comprising crossing a male sterile plant and a second plant which is male fertile, and obtaining seed of said male sterile plant, said male sterile plant and said second plant being selected such that said seed has integrated into its genome a first recombinant DNA molecule comprising a first DNA sequence which encodes a first gene product and a first promoter which is capable of regulating the expression of said first DNA sequence, and a second recombinant DNA molecule comprising a second DNA sequence which encodes a second gene product and a second promoter which is capable of regulating the expression of said second DNA sequence, one of said first and said second recombinant DNA molecules originating from said male sterile plant and the other of said first and second recombinant molecules originating from said second plant and said first and second gene products cooperating to selectively interfere with the function and/or development of cells of a plant that are critical to pollen formation and/or function of a plant grown from said seed whereby said plant grown from said seed is substantially male sterile. 
     The invention also relates to a method for producing hybrid seed which comprises cross-pollinating a progeny male sterile plant grown from the seed obtained in accordance with the above described method of the invention, with a suitable male fertile plant which does not contain a first recombinant DNA molecule or second recombinant DNA molecule as hereinbefore described, and harvesting hybrid seed from the progeny male sterile plant. 
     The methods of the invention described herein may be applicable to any species of pollen-bearing plant, particularly species of plants of the genus Brassica and the family Cruciferae (also known as Brassicaceae), the family Solanacae and more particularly other cultivars of Brassica napus. The methods of the invention will be illustrated below with reference to particular embodiments. 
     As hereinbefore mentioned the first DNA sequence may encode a first gene product which is capable of rendering a non-toxic substance cytotoxic to a cell of a plant which is critical to pollen formation and/or function and the second DNA sequence may encode a second gene product which is the non-toxic substance or encode a second gene product which is capable of converting a substance endogenous to a plant cell to said non-toxic substance. 
     A cell and/or tissue of a plant which is critical to pollen formation and/or function includes cells and/or tissues that are instrumental in the development or function of pollen, including cells and/or tissues from which pollen develops (e.g. premeiotic and uninucleate microspore cells), cells and/or tissues which form part of the male structure in which pollen develops (e.g. anther, tapetum or filament) and pollen itself. 
     The first DNA sequence may be any identifiable DNA sequence encoding gene products which are capable of rendering a non-toxic substance cytotoxic to a cell of a plant which is critical to pollen formation and/or function. Examples of such a DNA sequence includes a DNA sequence which encodes indole acetamide hydrolase (IamH) which converts naphthalene acetamide to the plant growth regulator alpha naphthalene acetic acid (NAA) which is toxic to developing pollen grains, or converts indole acetamide to indole acetic acid (IAA) which is a plant growth regulator. One source of the enzyme IamH is the bacterium Agrobacterium tumefaciens (Inze, D., et al, 1984, Mol. Gen. Genet. 194:265-74 and Koncz, C. and Schell, J., 1986, 204:383-396 re pPCV 311 plasmid derivative). Another source of an enzyme that is genetically equivalent to IamH is the gene coding for indole acetamide hydrolase from Pseudomonas savastanoi (Follin et al. (1985) Mol. Gen. Genet. 201: 178-185). 
     The first DNA sequence may also encode a gene product which is capable of rendering a non-toxic substance which is a protoxin cytotoxic to a cell of a plant that is critical to pollen formation and/or function. A protoxin has been identified which is inactive against plants but upon enzymatic conversion becomes cytotoxic. (Dotson, S. B. and G. M. Kishore, Isolation of a Dominant Lethal Gene with Potential Uses in Plants In The Genetic Dissection of Plant Cell Processes 1991). 
     The second DNA sequence may encode a second gene product which is the non-toxic substance or encode a second gene product which converts a substance which is endogenous to a plant cell into the non-toxic substance. For example, a cell may contain a DNA sequence which encodes IamH (which converts indole acetamide to cytotoxic levels of indole acetic acid), and a DNA sequence which encodes IamS. IamS converts tryptophan which is generally endogenous to plant cells, to indole acetamide which in turn is converted by IamH to cytotoxic levels of indole acetic acid. One source of the enzyme IaMS is the T-DNA gene 1 from the bacterium Agrobacterium tumefaciens (Inze, D., et al, 1984, Mol. Gen. Genet. 194:265-74). Another source of an enzyme that is functionally equivalent to IamS is the gene coding for tryptophan 2-mono-oxygenase from Pseudomonas savastanoi (Follin et al. (1985) Mol. Gen. Genet. 201: 178-185). The second DNA sequence may also encode non-toxic substances such as the above mentioned protoxin. 
     The promoters used in the methods of the invention may be a pollen specific promoter, an inducible promoter or a constitutive promoter. 
     A pollen specific promoter is a DNA sequence which regulates the expression of a DNA sequence selectively in the cells/tissues of a plant critical to pollen formation and/or function and/or limits the expression of such a DNA sequence to the period of pollen formation in the plant. Any identifiable pollen specific promoter may be used in the methods of the present invention. 
     DNA sequences have been isolated from a plant of the species Brassica napus ssp oleifera cv Westar which are expressed only in microspores and whose expression is essential to microspore function and/or development. A schematic representation of the restriction maps and coding regions of the microspore specific genes identified as L4 (SEQ. NOS. 3 and 4), L10 (SEQ. NOS. 5 and 6) , L16 (SEQ. NOS. 1 and 2) and L19 (SEQ. NOS. 7 and 8) have been detailed in published PCT Application No. PCT/CA90/00037. The complete nucleotide sequence of clones L4, and relevant sequences of L10, L16 and L19 have also been detailed in published PCT Application No. PCT/CA90/00037. The construction of vectors containing pollen specific promoters is illustrated in examples 1 to 6 herein and FIGS. 7A to 7E, 8 and 9 herein. 
     Preferably, the pollen specific promoter is a DNA sequence corresponding to the promoter sequence in the microspore specific genes identified as L4, L10, L16 and L19 above or a functional fragment thereof; or a chimeric promoter sequence containing one or more of a promoter sequence from the microspore specific genes identified as L4, L10, L16 and L19 or portions of such promoter sequences. The L4, L10 and L19 promoter sequences function in tobacco and other plant species. In addition, promoters derived from the L10 gene hybridize to other pollen RNA. 
     The preferred pollen specific promoters may be used in conjunction with naturally occurring flanking coding or transcribed sequences of the microspore specific genes or with any other coding or transcribed sequence that is critical to pollen formation and/or function. 
     It may also be desirable to include some intron sequences in the promoter constructs since the inclusion of intron sequences in the coding region may result in enhanced expression and specificity. Thus, it may be advantageous to join the DNA sequences to be expressed to a promoter sequence that contains the first intron and exon sequences of a polypeptide which is unique to cells/tissues of a plant critical to pollen formation and/or function. 
     Additionally regions of one promoter may be joined to regions from a different promoter in order to obtain the desired promoter activity. Specific examples of chimeric promoter constructs are the chimeric promoters contained in the vectors PAL 1107 (FIG. 7a) and PAL 1106 (FIG. 7b) as outlined in example 1 and in published PCT Application No. PCT/CA90/00037. 
     The first promoter or the second promoter used in the method of the invention may be an inducible promoter. An inducible promoter is a promoter that is capable of directly or indirectly activating transcription of a DNA sequence in response to an inducer. In the absence of an inducer the DNA sequence will not be transcribed. Typically the protein factor that binds specifically to an inducible promoter to activate transcription is present in an inactive form which is then directly or indirectly converted to the active form by the inducer. The inducer may be a chemical agent such as a protein, metabolite (sugar, alcohol etc.),a growth regulator, herbicide, or a phenolic compound or a physiological stress imposed directly by heat, salt, toxic elements etc. or indirectly through the action of a pathogen or disease agent such as a virus. A plant cell containing an inducible promoter may be exposed to an inducer by externally applying the inducer to the cell such as by spraying, watering, heating,or similar methods. Examples of inducible promoters include the inducible 70 KD heat shock promoter of D. melanogaster (Freeling, M., Bennet, D. C., Maize ADN 1, Ann. Rev. of Genetics 19:297-323) and the alcohol dehydrogenase promoter which is induced by ethanol (Nagao, R. T., et al., Miflin, B. J., Ed. Oxford Surveys of Plant Molecular and Cell Biology, Vol. 3., p. 384-438, Oxford University Press, Oxford 1986). The inducible promoter may be in an induced state throughout pollen formation or at least for a period which corresponds to the transcription of the DNA sequence of the recombinant DNA molecule(s). A promoter that is inducible by a simple chemical is particularly useful since the male sterile plant can easily be maintained by self-pollination when grown in the absence of such a chemical. 
     It will be appreciated that the term pollen used herein and in particular with reference to the inducible promoter described in the disclosure and claims, includes cells and/or tissues from which pollen develops (e.g. premeiotic and uninucleate microspore cells), cells and/or tissues which form part of the male structure in which pollen develops (e.g. anther, tapetum or filament) and pollen itself. 
     Another example of an inducible promoter is the chemically inducible gene promoter sequence isolated from a 27 kd subunit of the maize glutathione-S-transferase (GST II) gene. Two of the inducers for this promoter are N,N-diallyl-2,2-dichloroacetamide (common name: dichloramid) or benzyl-2-chloro-4-(trifluoromethyl)-5-thiazolecarboxylate (common name: flurazole). In addition a number of other potential inducers mat be used with this promoter as described in published PCT Application No. PCT/GB90/00110 by ICI. 
     Another example of an inducible promoter is the light inducible chlorophyll a/b binding protein (CAB) promoter, also described in published PCT Application No. PCT/GB90/00110 by ICI. 
     Inducible promoters have also been described in published Application No. EP89/103888.7 by Ciba-Geigy. In this application, a number of inducible promoters are identified, including the PR protein genes, especially the tobacco PR protein genes, such as PR-1a, PR-1b, PR-1c, Pr-1, PR-Q, PR-S, the cucumber chitinase gene, and the acidic and basic tobacco beta-1,3-glucanase genes. There are numerous potential inducers for these promoters, as described in Application No. EP89/103888.7. 
     The first or second promoter may be a constitutive promoter. A constitutive promoter is a promoter that functions in all, many, or a variety of cell types including cells/tissues critical to pollen formation and/or function. An example of such a constitutive promoter is CaMV 35S or preferably HP 101 which has been isolated from Brassica napus, which is particularly described below in reference to FIG. 10. 
     The restriction map of a Brassica napus genomic clone (HP 101) deposited Jan. 26, 1990 with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Md, 20852, U.S.A. as pPAL0101/E. coli strain DH5 alpha under accession number ATCC 68210 that contains a constitutively expressed gene is shown in FIG. 10 and the fragment of this clone that contains a 5&#39; promoter region along with a portion of transcribed sequence is identified. The fragment was isolated by first cloning the small 2.5 kb Eco RI fragment in pGEM 4Z, and obtaining a subclone that had this fragment inserted in the indicated orientation relative to the polylinker of pGEM 4Z. This subclone, pPAL 0101, was then digested with Eco RI, treated with Klenow fragment, then digested with Bam HI, which releases the promoter/transcribed region indicated. This fragment was cloned into Hinc II-Bam HI cut pGEM 4Z, resulting in the subclone pPAL HP101. The subclone can be used for the isolation of promoter sequences in vector constructs that utilize a constitutive promoter. 
     Recombinant DNA molecules containing any of the DNA sequences and promoters described herein may additionally contain selection marker genes which encode a selection gene product which confer on a plant cell resistance to a chemical agent or physiological stress, or confers a distinguishable phenotypic characteristic to the cells such that plant cells transformed with the recombinant DNA molecule may be easily selected using a selective agent. A preferred selection marker gene is neomycin phosphotransferase (NPT II) which confers resistance to kanamycin and the antibiotic G-418. Cells transformed with this selection marker gene may be selected for by testing in vitro phosphorylation of kanamycin using techniques described in the literature or by testing for the presence of the mRNA coding for the NPT II gene by Northern blot analysis in RNA from the tissue of the transformed plant. Transformed plant cells thus selected can be induced to differentiate into plant structures which will eventually yield whole plants. It is to be understood that a selection marker gene may also be native to a plant. 
     The male sterile plant may be produced by exposing a plant carrying a male sterile trait to a sterility actuating agent. For example, the male sterile plant may be produced by preparing a plant having integrated into its genome a first DNA sequence which encodes a first gene product which is capable of rendering a non-toxic substance cytotoxic to a cell of a plant which is critical to pollen formation and/or function regulated by a pollen specific promoter, and exposing the plant to a sterility actuating agent which is the non-toxic substance. 
     The male sterile plant may also be produced by preparing a plant having integrated into its genome a first DNA sequence which encodes a first gene product which is capable of rendering a non-toxic substance cytotoxic to a cell of a plant which is critical to pollen formation and/or function and a first promoter and a second DNA sequence which encodes a second gene product which is the non-toxic substance and a second promoter, the first or second promoter being an inducible promoter which is capable of being activated by a sterility actuating agent i.e. an inducer, throughout pollen formation, and the other of the first and second promoters being a pollen specific promoter, and exposing the plant to the inducer. 
     The male sterile plant may also be produced by preparing a plant having integrated into its genome a third DNA sequence which is an anti-sense gene which encodes an RNA which substantially interferes with the expression of a sense gene that is critical to pollen formation and/or function or a DNA sequence which encodes a substance which is cytotoxic to cells of a plant that are critical to pollen formation and/or function regulated by an inducible promoter, and exposing the plant to the inducer. The male sterile plant may also be produced by preparing a plant having integrated into its genome a 3rd DNA sequence which is an anti-sense gene which encodes an RNA which substantially interferes with the expression of a sense gene which confers on cells of a plant resistance to a chemical agent or physiological stress regulated by a pollen specific promoter, and exposing the plant to the chemical agent or physiological stress. The 3rd DNA sequence may be located on the same recombinant DNA molecules as the first or second DNA sequences which may be integrated into the genome of the male sterile plant or the 3rd DNA sequence may be located on a different recombinant DNA molecule. These and other methods which may be used for producing male sterility are described in Australian Patent Application Serial No. 611258 and in published PCT Application No. PCT/CA90/00037. 
     A recombinant DNA molecule containing any of the DNA sequences and promoters described herein may be integrated into the genome of the male sterile plant or second plant by first introducing a recombinant DNA molecule into a plant cell by any one of a variety of known methods. Preferably the recombinant DNA molecule(s) are inserted into a suitable vector and the vector is used to introduce the recombinant DNA molecule into a plant cell. 
     The use of Cauliflower Mosaic Virus (CaMV) (Howell, S. H., et al, 1980, Science 208: 1265) and gemini viruses (Goodman, R. M., 1981, J. Gen. Virol. 54: 9) as vectors has been suggested but by far the greatest reported successes have been with Agrobacteria sp. (Horsch, R. B., et al, 1985, Science 227: 1229-1231). Methods for the use of Agrobacterium based transformation systems have now been described for many different species. Generally strains of bacteria are used that harbour modified versions of the naturally occurring Ti plasmid such that DNA is transferred to the host plant without the subsequent formation of tumours. These methods involve the insertion within the borders of the Ti plasmid the DNA to be inserted into the plant genome linked to a selection marker gene to facilitate selection of transformed cells. Bacteria and plant tissues are cultured together to allow transfer of foreign DNA into plant cells then transformed plants are regenerated on selection media. Any number of different organs and tissues can serve as targets for Agrobacterium mediated transformation as described specifically for members of the Brassicaceae. These include thin cell layers (Charest, P. J., et al, 1988, Theor. Appl. Genet. 75: 438-444), hypocotyls (DeBlock, M., et al, 1989, Plant Physiol. 91: 694-701), leaf discs (Feldman, K. A., and Marks, M. D., 1986, Plant Sci. 47: 63-69), stems (Fry J., et al, 1987, Plant Cell Repts. 6: 321-325), cotyledons (Moloney M. M., et al, 1989, Plant Cell Repts 8: 238-242) and embryoids (Neuhaus, G., et al, 1987, Theor. Appl. Genet. 75: 30-36). It is understood, however, that it may be desirable in some crops to choose a different tissue or method of transformation. 
     It may be useful to generate a number of individual transformed plants with any recombinant construct in order to recover plants free from any position effects. It may also be preferable to select plants that contain more than one copy of the introduced recombinant DNA molecule such that high levels of expression of the recombinant molecule are obtained. 
     Other methods that have been employed for introducing recombinant molecules into plant cells involve mechanical means such as direct DNA uptake, liposomes, electroporation (Guerche, P. et al, 1987, Plant Science 52: 111-116) and micro-injection (Neuhaus, G., et al, 1987, Theor. Appl. Genet. 75: 30-36). The possibility of using microprojectiles and a gun or other devise to force small metal particles coated with DNA into cells has also received considerable attention (Klein, T. M. et al., 1987, Nature 327: 70-73). 
     It may also be possible to produce the male sterile plant by preparing a plant carrying a male sterile trait by fusing cells of a plant cell line containing cells having recombinant DNA molecules containing the DNA sequences and promoters described herein with cells of plant species that cannot be transformed by standard methods. A fusion plant cell line is obtained that carries a genetic component from both plant cells. Fused cells that carry the recombinant DNA molecule(s) can be selected and in many cases regenerated into plants that or carry the male sterile trait. 
     It is contemplated in some of the embodiments of the process of the invention that a plant cell be transformed with a recombinant DNA molecule containing at least two DNA sequences or be transformed with more than one recombinant DNA molecule. The DNA sequences or recombinant DNA molecules in such embodiments may be physically linked, by being in the same vector, or physically separate on different vectors. A cell may be simultaneously transformed with more than one vector provided that each vector has a unique selection marker gene. Alternatively, a cell may be transformed with more than one vector sequentially allowing an intermediate regeneration step after transformation with the first vector. Further, it may be possible to perform a sexual cross between individual plants or plant lines containing different DNA sequences or recombinant DNA molecules preferably the DNA sequences or the recombinant molecules are linked or located on the same chromosome, and then selecting from the progeny of the cross, plants containing both DNA sequences or recombinant DNA molecules. 
     Expression of recombinant DNA molecules containing the DNA sequences and promoters described herein in transformed plant cells may be monitored using Northern blot techniques and/or Southern blot techniques. The formation of microspores in plants which contain recombinant DNA molecule(s) such that they are rendered male sterile, is first monitored by visual microscopic examination of the anther structure. As maturation of the flower occurs, anther formation is expected to be delayed or completely inhibited such that no mature pollen grains are formed or released. 
     Where more than one recombinant DNA molecule of the invention is used to produce a male sterile plant as in the methods of the present invention, the recombinant DNA molecules may be inserted in the same chromosome pair in separate isogenic plant lines. The respective lines are preferably made homozygous for the respective recombinant DNA molecule(s) /gene prior to crossing the lines to produce a male sterile plant. Where a first and a second recombinant molecule are integrated into the same chromosome in the isogenic plant lines, a cross of these lines results in the first and second recombinant DNA molecules being located on separate chromosomes of the same chromosome pair in the male sterile plant. Consequently, when the male sterile plant is crossed with a suitable male fertile plant of a different line, both chromosomes of the chromosome pair segregate into separate F1 progeny with the result that the first and second recombinant DNA molecules are not expressed in the same plant. Thus, the F1 hybrid seed is fully fertile and thus has restored fertility. If the two recombinant DNA molecules are integrated into different chromosomes in the male sterile plant, then a portion of the F1 hybrid seed will be male sterile since there is a 25% probability of co-segregation of the chromosomes containing both recombinant DNA molecules into the male sterile plant. This latter approach may be advantageous with respect to outcrossing species. When the F1 male fertile plants outcross, a portion of the F2 seed will inherit both chromosomes containing the first and second recombinant DNA molecules and consequently will be male sterile. Where the seed is the commodity of commerce, it is advantageous for seed producing companies to use a scheme for hybrid seed production, where the saving of F2 hybrid seed is discouraged. The outcrossing in the F1 hybrid plants results in partial male sterility in the F2 generation, thereby reducing the seed yield of F2 plants, which is commercially desirable. An example of this method is as follows: a first male sterile plant line incorporating in its genome a recombinant DNA molecule having an IamH gene encoding IamH which converts non-toxic IAM to toxic levels of IAA, may be crossed with a second plant line having a genome incorporating a second recombinant DNA molecule having an IamS gene which converts tryptophan to IAM. 
     As indicated above, it may be desirable to produce plant lines which are homozygous for a particular gene. In some species this is accomplished rather easily by the use of anther culture or isolated microspore culture. This is especially true for the oil seed crop Brassice napus (Keller and Armstrong, Z. Pflanzenzucht 80: 100-108, 1978). By using these techniques, it is possible to produce a haploid line that carries the inserted gene and then to double the chromosome number either spontaneously or by the use of colchicine. This gives rise to a plant that is homozygous for the inserted gene, which can be easily assayed for if the inserted gene carries with it a suitable selection marker gene for detection of plants carrying that gene. Alternatively, plants may be self-fertilized, leading to the production of a mixture of seed that consists of, in the simplest case, three types, homozygous (25%), heterozygous (50%) and null (25%) for the inserted gene. Although it is relatively easy to score null plants from those that contain the gene, it is possible in practice to score the homozygous from heterozygous plants by southern blot analysis in which careful attention is paid to the loading of exactly equivalent amounts of DNA from the mixed population, and scoring heterozygotes by the intensity of the signal from a probe specific for the inserted gene. It is advisable to verify the results of the southern blot analysis by allowing each independent transformant to self-fertilize, since additional evidence for homozygosity can be obtained by the simple fact that if the plant was homozygous for the inserted gene, all of the subsequent plants from the selfed seed will contain the gene, while if the plant was heterozygous for the gene, the generation grown from the selfed seed will contain null plants. Therefore, with simple selfing one can easily select homozygous plant lines that can also be confirmed by southern blot analysis. 
     Two techniques may be used to produce plant lines which carry genes that segregate in a similar fashion or are on the same chromosome or a set of chromosome pairs. One may be a simple crossing strategy in which two transformants that are homozygous for a single inserted gene are crossed to produce F1 seed. The progeny plants from the F1 seed (F1 plant generation) may be crossed with a recipient plant and the segregation of the two inserted genes is determined (F2 plant generation). For example, where the IamH and IamS genes are the inserted genes, the F1 plants grown from the F1 seed will be male sterile. If the original transformants are homozygous for a single inserted gene, when crossed with a non-transformed plant to produce F2 seed, the F2 plants will be 100% male fertile if the two transformants originally used for the production of the F1 seed carried the IamH and the IamS genes on the same chromosome or in the same linkage group. If the genes are in separate linkage groups or on different chromosomes, a variable degree of male sterility will be seen, in theory 25% of the plants will be male sterile if the genes segregate completely independently of each other. This approach allows for the selection of breeding lines from the homozygous transformed plant lines that contain the IamS and IamH genes which will segregate substantially 100% in the hybrid seed sold for commercial use. 
     An alternative strategy may make use of extensive genetic maps available for many commercially grown crops and the many easily scoreable markers that are known for most linkage groups or chromosomes. In some cases, linkage groups and chromosomes may be equivalent, whereas in others, there may be more than one linkage group assigned to each chromosome. When there is a marker for each chromosome, identification of the chromosome into which the recombinant gene has been inserted is relatively simple. A cross is made between each individual transformant and a recipient plant that allows for visualization of the marker(s). 
     If there are scoreable markers that have been localized to each of the chromosomes in the plant, and the markers are scoreable in the generation produced by this cross, one can localize the segregation of the inserted gene with the marker, thereby establishing the chromosomal location of that gene. This therefore allows for the chromosomal or more importantly the linkage group with which the inserted gene segregates. Many crops such as corn, tomato and many cereal crops have extensive genetic maps that allow for the identification of the chromosome containing the inserted gene. It is contemplated that as more detailed chromosome maps are made, especially with the use of RFLP (restriction fragment length polymorphism) maps, the assignment of inserted genes to particular chromosomes will easily be done for most commercial crop species. 
     As a means of confirmation, or in plant species where chromosomal markers are not known, it is possible to use a technique called pulse-field electrophoresis (originally described by Schwartz and Cantor, Cell, 37: p67; 1984) to determine if different transformed plants contain inserted genes on the same chromosome. Pulse-field electrophoresis is a technique that can separate large DNA pieces, even chromosomal size, into a reproducible pattern on a gel. When this is done, it is possible to process this gel such that the chromosome spots can be analyzed by southern blotting techniques, localizing the inserted gene to a chromosome spot. When the entire population of primary transformants are analyzed in this fashion, it is a simple task to choose the two transformants that carry the inserted genes on the same chromosome spot. 
     In one embodiment of the process of the invention for producing hybrid seed a male sterile plant having a genome incorporating a recombinant DNA molecule having a first DNA sequence encoding a protein or polypeptide which renders a non-toxic substance substantially cytotoxic to a cell of a plant which is critical to pollen formation and/or function and a pollen specific promoter is crossed with a second plant which contains a second recombinant DNA molecule having a second DNA sequence which encodes a second gene product which converts a substance which is endogenous to a plant cell to the non-toxic substance. Preferably, the male sterile plant and second plant used in this method are isogenic and each line carries a homozygous loci for the first DNA sequence or the second DNA sequence. Most preferably the first and second DNA sequences are located on the same chromosome pair of the plant lines, such that in any cross of the two lines a single chromosome pair contains both the first and second DNA sequences. The first plant line is made male sterile by exposing the first plant line to the non-toxic substance. The protein or polypeptide encoded by the recombinant DNA molecule incorporated in the genome of the first plant line will render the non-toxic substance toxic in cells of the plant which are critical to pollen formation and/or function, thus producing a male sterile plant line. The male sterile plant line also preferably has a selection marker gene linked to the first DNA sequence encoding the protein or polypeptide which renders a non-toxic substance cytotoxic to facilitate harvesting of the seeds having cells containing the first and second DNA sequences. 
     When the first male sterile plant line and the second plant line are crossed, the first male sterile plant line produces seeds having cells containing the DNA sequence encoding a gene product capable of synthesizing the non-toxic substance (e.g. IAM) and the DNA sequence encoding the protein or polypeptide (IamH) which renders the non-toxic substance cytotoxic (e.g. IamH converts IAM to toxic level of IAA). The seed having cells containing the first and second DNA sequences will produce male sterile plants which may be pollinated with a male fertile line to produce commercial hybrid seed. If the first and second DNA sequences are located on the same chromosome or in the same linkage group, the DNA sequences will segregate completely in the F1 hybrid seed and the hybrid seed will be substantially male fertile. 
     Advantage is taken in the above-mentioned preferred method of the fact that-most plant species produce, per plant, many hundreds of seeds. In oilseed Brassica for example, one plant, under normal conditions can produce one thousand seeds. Using the method described above, one can expect a thousand-fold increase in seeds per unit area sprayed with the non-toxic substance. That is to say that, for example, when two isogenic lines are produced that carry the IamS and IamH genes, the first pre-production step involves the use of NAM to cause male sterility in the plant line that carries only the IamH gene. When cross pollinated with the pollen from the plant that contains the IamS gene, one can expect up to one thousand seeds per unit area, each seed capable of growing into a male sterile plant. When these seeds are planted and crossed with a male sterile plant, one can expect one thousand seeds per unit area. Therefore, if one were to plant one acre of the plant line carrying the IamH gene and the pollinator carrying the IamS gene, this acre would need to be sprayed with NAM. From this one acre however, enough seed would be obtained to grow 1000 acres of male sterile plants and pollinators, and from these 1000 acres, enough hybrid seed with restored fertility would be obtained to plant 1,000,000 acres of hybrid crop. The amount of management required to produce this hybrid seed is reduced over conventional methods because of the pre-production amplification step employed. If the IamH gene is linked to a herbicide resistance gene, one can plant the fields randomly to ensure high rates of cross pollination and use the herbicide to kill the pollinator plants after flowering. This method therefore allows for efficient hybrid seed production over methods where hybrid seed is harvested directly following the first cross pollination. 
     A preferred embodiment of the above method is described in more detail below with reference to FIGS. 1A, 1B and 2. As illustrated in FIGS. 1A and 1B, the method employs two plant lines which are homozygous, respectively, for the IamH gene (plant line A2) and the IamS (plant line A1) genes and otherwise isogenic. These genes are located on the same chromosome pair in each plant, preferably at the same genetic locus or a position such that the chance of a crossing over event is substantially reduced. Accordingly, plants produced from a cross of these two isogenic lines will contain the IamS and the IamH gene respectively on different chromosomes of a single chromosome pair. This will ensure that the two genes will segregate when this plant is crossed with a male fertile plant. 
     To produce the hybrid seed, a two step procedure is used. The first step involves a pre-production of an isogenic male sterile line, the second step is the hybrid seed production itself. 
     To accomplish the first step the following approach is used: The two isogenic lines A1 and A2 are planted in rows as shown, and when flowering starts, the plots are sprayed with NAM (naphthalene acetamide). NAM is also a substrate for the IamH enzyme. This chemical is a non-toxic version of the plant growth regulator NAA, and the action of the IamH gene converts NAM to NAA. Under the control of the pollen specific promoter, the IamH gene only is expressed in pollen of the A2 line, and as such NAA is only made in pollen of the A2 line. Since NAA is a plant growth regulator, normal anther and microspore development is altered, leading to male sterility in the A2 plant line when treated with NAM. 
     The IamH enzyme can use a number of other substrates, including indole acetamide, indole-3-acetonitrile, conjugates between glucose and IAA and conjugates between myo-inositol and IAA. (Follin et al. (1985) Mol. Gen. Genet. 201: 178-185). Spraying with any of these compounds will produce the same effect as spraying with NAM; namely male sterility in plants expressing the IamH gene. 
     The plants which contain the IamS gene under the control of the pollen specific promoter (plant line A1) are not affected by the NAM, since they are unable to convert NAM to NAA, therefore these plants remain fully male fertile and can cross pollinate the A2 plants which have now become male sterile after treatment with NAM. On the A2 line, seed is produced that contains both the IamH and IamS genes under the control of pollen specific promoters (plant seed A2/A1). 
     The seed produced on the A2 line (plant seed A2/A1) is harvested. This harvesting can be done by harvesting specific rows. Alternatively, the IamH gene (A2) may be linked to a gene for herbicide resistance so that the herbicide can be used for the roguing of the plant line A1. Herbicide application takes place after flowering and will kill the A1 plants so that only seed that has the genotype A1/A2 is produced. The seed harvested from such a field will produce substantially 100% male sterile plants. The cross produces plants that express both the IamS and the IamH genes only in the pollen. This leads to the conversion of tryptophan, an amino acid normally found in plant cells to IAM (indole acetamide) via the IamS activity and finally to IAA (indole acetic acid) via the IamH activity. The molecule IAA is a plant growth regulator that is cytotoxic in greater than normal concentrations in a cell of a plant that is critical to pollen formation and/or function, particularly, in the developing pollen grains or anther of the plant. Since the IAA and the precursor IAM are small molecules that can be transferred from cell to cell via diffusion or active transport, altered growth regulator levels are seen throughout the anther. This altered growth regulator level leads to abnormality in pollen and anther development, producing a male sterile plant. This plant can be pollinated with a male fertile line leading to commercial hybrid seed. 
     For the production of hybrid seed, the male sterile isogenic line can be planted in rows along side of a suitable male fertile plant, and the hybrid seed produced on the male sterile plant can be harvested. If the IamH gene is linked to a herbicide resistance gene, harvesting of hybrid seed is facilitated by using the herbicide to eliminate pollinator plants after cross pollination. The entire field can then be combined. All seed produced will therefore be hybrid. If the two genes (IamS and IamH) are located on the same chromosome or in the same linkage group, these two genes will segregate completely in the F1 hybrid seed. Since the plants will contain either the IamS or the IamH gene, but not both, the seed produced by this hybrid cross will be substantially 100% male fertile. Therefore the plants grown from the seed of this cross will be fully fertile and set normal levels of seed. The F2 seed that results from the harvest of this field however will contain a variable degree of male sterility, since in theory 12.5% or 2 out of 16 of the plants grown from this F2 seed will contain both the IamS and the IamH genes, as illustrated in FIG. 2. 
     Where there is poor outcrossing, the F2  sterility will be lower than the maximum of 12.5% since a portion of the plants will self and the progeny of selfed plants will not contain both genes. Accordingly, these plants will remain fertile in the F2 generation. 
     It is contemplated that as a variation of the above particularly preferred method, a number of different ways of producing the toxic molecule specifically in pollen can be envisioned. In all approaches, at least one step in the production of the cytotoxic molecule has to take place specifically within the pollen cells or anthers. For instance, it is possible to use a constitutively expressed IamS gene in a plant and to subsequently cross that plant with a plant that contains the IamH gene under the control of a pollen specific promoter such that IAM is produced in all cells of the plant, but the growth regulator IAA is produced only in pollen cells due to the action of the pollen specific IamH gene. Conversely , it is possible to have IamH constitutively expressed in a plant, and cross this plant with a plant that contains a pollen specific promoter driving the IamS gene. In this situation, the growth regulator IAA is only produced in pollen cells. It should be cautioned that in this case, one cannot use NAM to induce transitory male sterility in the plant that contains the IamH gene, since that application of NAM would be lethal to the plant. In this case then hand pollination would be the preferred way of combining those genes. With regards to these methods the preferred embodiment of the present invention places both the IamH gene and the IamS gene under the control of pollen specific promoters and preferably using the same pollen specific promoter or a pollen specific promoter whose expression substantially overlaps that of the other to each independently drive the expression of these two genes. Additionally, by linking the IamH gene to a selectable agent such as a herbicide, hybrid seed production is greatly facilitated. 
     Any number of genes could be used to carry out the process and methods of the invention providing that the simultaneous production of two or more enzymatic or synthetic activities specifically in pollen leads to the production of a substance which is toxic or inhibitory to normal pollen growth or specifically interferes with anther or pollen development. This implies that one or more of these activities could be constitutive in the plant, but that the final combination of all enzyme activities be limited to pollen. It is also envisioned that one of these activities could be inducible by natural or artificial means such that sterility could be induced in plants. 
     Specifically one embodiment of this method uses a plant line that carries a IamS gene under the control of an inducible promoter and a IamH gene under the control of a pollen specific promoter. These genes are preferably linked, but could be unlinked. When grown under inductive conditions, the plant becomes male sterile and can be pollinated by a suitable male fertile plant. The suitable plant could also carry a IamS gene under the control of a pollen specific promoter such that the progeny of this cross will be male sterile. These plants could then be crossed with a male fertile plant, producing hybrid seed. 
     The above mentioned embodiment employing a plant that carries a first recombinant DNA molecule having a DNA sequence encoding IamH and an inducible promoter, and a second recombinant DNA molecule having a gene encoding IamS regulated by a pollen specific promoter is described below with reference to FIGS. 5A, 5B and 6. It will be appreciated that the gene encoding IamH and are inducible promoter may be located on the second recombinant DNA molecule having the gene encoding IamS regulated by the pollen specific promoter. As illustrated in FIGS. 5A and 5B, the method employs two plant lines which are homozygous, respectively, for the first recombinant DNA molecule and second recombinant DNA molecule (plant line A2) and a first recombinant DNA molecule having a gene encoding IamH and a pollen specific promoter (plant line A1) and are otherwise isogenic. These genes are preferably located at the same genetic locus or a position such that the chance of a crossing over event on corresponding chromatids of a chromosome pair are substantially reduced. Accordingly, plants produced from a cross of these two isogenic lines will contain the first and second recombinant DNA molecules and the first recombinant DNA molecule on different chromatids of a single chromosome pair. This will ensure that the genes will segregate when this plant is crossed with a male fertile plant. 
     To produce the hybrid seed, a two step procedure is used. The first step involves a pre-production of an isogenic male sterile line, the second step is the hybrid seed production itself. 
     To accomplish the first step the following approach is used: The two isogenic lines A1 and A2 are planted in rows as shown, and when flowering starts, the plots are sprayed with an inducer. With reference to FIGS. 5A and 5B, the inducer is a chemical inducer. This chemical causes induction of the inducible promoter in the first recombinant DNA molecule such that expression of the gene encoding the IamH occurs in the A2 line. The IamS gene under the control of the pollen specific promoter is expressed only in pollen of the A2 line, and as such IAA is only made in pollen of the A2 line. In the presence of the enzyme IamH, IAM is rendered cytotoxic. Accordingly, normal anther and microspore development is altered, leading to male sterility in the A2 plant line when treated with the chemical inducer. 
     The plants which contain an IamH gene under the control of the pollen specific promoter (plant line A1) are not affected by the chemical inducer, since these plants do not produce IAM and are thus are unable to produce cytotoxic levels of IAA. Therefore these plants remain fully male fertile and can cross pollinate the A2 plants which have now become male sterile after treatment with the chemical inducer. On the A2 line, seed is produced that contains the first recombinant DNA molecule and the second recombinant DNA molecule from the A2 and the first recombinant DNA molecule from the A1 line (plant seed A2/A1). 
     The seed produced on the A2 line (plant seed A2/A1) is harvested, more particularly described as discussed above. The seed harvested from such a field will produce substantially 100% male sterile plants which may be pollinated with a male fertile line leading to a commercial hybrid seed as discussed above. 
     Table 1 outlines a number of possible embodiments according to the process of the invention. It is to be understood that this table does not represent all the possible embodiments but is merely representative of some of the various embodiments. In this Table the IamH and IamS genes are used to illustrate the methods but it is understood that any two DNA sequences which encode gene products which cooperate to selectively interfere with the function and/or development of cells that are critical to pollen formation and/or function may be utilized in the methods of the invention. 
     The following examples are further provided for illustrative purposes only and are in no way intended to limit the scope of the present invention. 
     EXAMPLES 
     Example 1 
     The construction of 6 vectors containing promoter and promoter fragments from the clone L4 is described in FIG. 7 (SEQ. NOS. 3 and 4) (a,b,c,d,e). The first step in the construction of these vectors was accomplished by first subcloning the Eco R1-Sst 1(nucl.1-2132) fragment containing the first gene of clone L4 (235 base pairs of promoter/exon/intron/second exon) in the commercially available vector pGEM-4Z(Promega Biotech, Madison, Wis., U.S.A.) using the Eco R1-Sst 1 sites of the polylinker of this vector. This plasmid was named pPAL 0402. The 2.7 Kb Eco RI fragment of clone L4 that contains the third gene (Bp4C) was then cloned into the Eco RI site of pGEM 4Z, leading to a plasmid called pPAL 0411. The plasmid pPAL 0402 was then digested with Eco R1 and the 2.7 Kb Eco R1 fragment from pPAL 0411(nucl. 5859-8579) that contains the gene number three (Bp4C) from clone L4 was added to it. Clones were recovered that contained this inserted 2.7 Kb Eco R1 fragment in both orientations relative to the promoter region of the first gene. A clone that contained this third gene fragment in a orientation such that the promoter from the third gene was opposite to the promoter in the first gene was chosen and called pPAL 0403. The plasmid pPAL 0403 contains the entire third gene from clone L4 oriented in such a fashion as to have the promoter region immediately adjacent to the 235 basepair promoter region of the first gene in pPAL 0403. This plasmid, pPAL 0403 was digested with Dde I, producing a fragment of approximately 1.9 Kb. The Dde I sites are located at nucleotides 303 and 7366. Because of the orientation of these fragments, digestion with Dde I produces a 1.9 Kb fragment. This 1.9 Kb fragment contains a copy of the third gene (Bp4C) oriented such that the direction of transcription of this third gene is from right to left, fused to the 235 base pair promoter fragment from the first gene of clone L4 (Bp4A) which is transcribed from left to right, ending in a Dde I site that is located 67 basepairs down stream of the major start site of transcription and precedes that ATG start of translation codon by 2 nucleotides. This 1.9 Kb Dde I fragment was made blunt with Klenow fragment and cloned into the Xba 1 site of the polylinker region of pGEM 4Z previously made blunt ended with Klenow fragment. The resultant plasmid pPAL 0408, was recovered and subsequently was digested with Sal 1 and Sst 1, which releases the cloned Dde 1 fragment bordered by on the left hand side, (nucl 7366) Sal 1 and on the right hand side (nucl 303) of this construct and contains a portion of the polylinker of pGEM 4Z containing the following unique sites: Bam HI, Sma I, Kpn I, and Sst I restriction enzyme sites. This Sal 1-Sst 1 fragment was cloned into the Sal 1-Sst 1 sites of PAL 1001. PAL 1001 is the binary vector Bin 19 (described by Bevan, M., Nucleic Acids Res., 1984, 12:8711-8721) to which has been added the nos ter polyadenylation signal as a 260 bp Sst 1-Eco R1 fragment isolated from the plasmid pRAJ 221 (available from Clonetech Laboratories, Palo Alto, Calif. U.S.A.) in the Sst 1-Eco R1 sites of the polylinker region of Bin 19. This nos ter is identified as a stippled box. The binary transformation vector that resulted from the insertion of the Sal I-Sst I fragment of pPAL 0408 into PAL 1001 was named PAL 1107. The details of the construction are shown in FIG. 7a. This vector has a copy of the third gene oriented such that the direction of transcription of this third gene is from right to left, fused to the 235 base pair promoter fragment from the first gene of clone L4 which is transcribed from left to right, followed by a polylinker with unique sites for the insertion of DNA which consist of: Bam HI, Sma I, Kpn I and Sst I followed by the nos ter signal. This vector has the feature in that additional 5&#39; non-coding sequences were placed upstream to the 235 base pair core promoter on Bp4A, but these additional 5&#39; sequences were in a opposite orientation. The provision of these sequences in this orientation does not affect the pollen specificity of the core 235 base pair promoter. 
     In addition to this vector, similarly structured vectors were made which contained essentially the same type of gene promoter arrangement but contained the intron of the first gene (Bp4A) of clone L4. Intron sequences in plant genes have been shown in some cases to play a role in gene expression. This intron containing vector was constructed by making a deletion series of the clone pPAL 0402. pPAL 0402 was first digested with Pst I and Sma I. Exonuclease III was used to unidirectionally digest the DNA as shown (FIG. 8b). After S1 nuclease treatment and repair with Klenow, the plasmid was relegated and clones that have had different portions of the coding regions of gene Bp4A digested out of them were recovered. Deletion subclones were sequenced. One was chosen for vector constructs. This is referred to as deletion 23B. This subclone represented a deletion that has most of the second exon of gene Bp4A removed but contains the intron splice site and first exon of gene Bp4A. This subclone contains a portion of the clone L4 that extends from nucleotide 1 to nucleotide 1166. To this subclone was added the 2.7 Kb Eco R1 fragment from pPAL 0411 that contains the third gene of L4 (Bp4C) in such an orientation that the direction of transcription of the third gene is from right to left (as in PAL 1107, pPAL 0408), fused to the 235 base pair promoter region from the first gene of clone L4 which is oriented to transcribe from left to right followed by the first exon of gene 1, the entire intron of gene 1 and 33 nucleotides of the second exon of gene Bp4A from clone L4. This plasmid containing deletion 23B and the 2.7 Kb Eco RI fragment containing the third gene fragment was named pPAL 0406. This plasmid was digested with Hind III, which yields a fragment containing a small portion of the promoter of the third gene as well as the entire promoter of the first gene, first exon, intron and a portion of the second exon. This Hind III fragment was inserted into the Hind III site of PAL 1001, resulting in the vector PAL 1106 (deletion 23B derived). This vector has in the following order, A portion of the promoter from the third gene in clone L4, the entire 235 base pair promoter of the first gene in clone L4, followed by the first exon, the intron and a portion of the second exon of gene 1 of clone L4, followed by a polytinker containing the following unique cloning sites: Sal I, Xba I, Bam HI, Sma I, Kpn I and Sst I and the nos ter polyadenylation signal. The construct is shown in FIG. 7b. 
     Example 2 
     Additional constructs with the promoter regions of the genes contained in clone L4 were done in order to provide a number of suitable vectors that are useful for pollen specific expression of gene sequences. The three genes within clone L4 (Bp4A, Bp4B, Bp4C) show very near-exact DNA homology and this is most apparent between the first (Bp4A) and third (Bp4C) gene. The second gene (Bp4B) is a homologous copy that has undergone sequence changes that appear to have lead to inactivation. The extensive similarity between the first, second and third genes in clone L4 is also maintained in the promoter region such that out of the first 235 nucleotides of the first and third gene promoter regions there are only 5 nucleotides that differ between them. Downstream of the TATA box in these two promoters the only difference between them is the presence of one additional nucleotide at the start of transcription. For example, comparison of Promoter 1, Bp4A, partially represented as: . . . TATGTTTtAAAA . . . (SEQ. NO. 9) with Promoter 3, Bp4C, partially represented as: . . . TATGTTTAAAA . . . (SEQ. NO. 10) shows that the transcribed region underlined and the single nucleotide difference in lower case. However, within the sequence of the first gene there is a nucleotide change that introduces a Dde I site (nucl 303) in the untranslated 5&#39; leader sequence upstream of the ATG start codon that is not present in the untranscribed leader sequence of the third gene in clone L4. Chimeric promoter constructs were made which utilized this Dde I site in the first gene to combine with sequences from the third gene promoter. The region of the first promoter used for these constructs consisted of the sequences contained between the Sna BI site (nucl 210) near the TATA box to the Dde I site located immediately upstream of the ATG start codon in the first gene (nucleotide 303 is the first nucleotide in the recognition sequence for Dde I). The other region of this chimeric promoter (5&#39; of the TATA box) was a fragment extending from the Eco R1 site of the third promoter (nucleotide 5858) to the Sna B1 site near the TATA box (nucleotide 6272). Therefore to facilitate construction of these pollen specific vectors, the following reconstructions were performed. 
     The Eco R1 to Dde 1 fragment that encompasses the promoter region of the first gene in clone L4 was isolated by first cutting pPAL 0402 with Dde 1, blunting with Klenow, and then cutting with Eco R1. The 235 base pair fragment corresponding to this region was cloned into the Eco R1-Sma 1 sites of pGEM 4Z. This plasmid (pPAL 0422), was then cut with Eco R1 and Sna B1. A DNA fragment that contained the Eco RI to Sna BI portion of the promoter for gene 3 in clone L4 was isolated by digesting pPAL 0411 with Eco R1 and Sna B1. This released an approximately 415 base pair Eco RI (nucl.5858) to Sna BI (nucl.6272) fragment that represents most of the 5&#39; region of the gene 3 promoter from clone L4 (the Sna B1 recognition site is 2 base pairs downstream of the TATA box). This Eco R1-Sna B1 fragment was used to replace the shorter Eco R1-Sna B1 fragment removed for the first promoter subclone (pPAL 0422), reconstructing a promoter fragment of approximately 550 base pairs. This plasmid is referred to as pPAL 0421. This chimeric promoter fragment contains 415 base pairs of the promoter of gene three in clone L4, followed by approximately 99 nucleotides of the first gene promoter/untranslated leader sequence. 
     Example 3 
     For construction of a pollen specific cassette vector, the following plasmids were first constructed. The first plasmid constructed contained the nos ter polyadenylation signal with a polylinker in front of the nos ter signal. This was accomplished by first isolating from pRAJ 221 the nos ter as a Sst 1-Eco R1 fragment and this fragment was cloned in pGEM 4Z using the Sst 1 and Eco R1 sites in the polylinker. This subcloned is referred to as pPAL 001. To pPAL 001, a fragment coding for neomycin phosphotransferase (NPT II) derived from the plasmid pRAJ 162 was added to it in the anti-sense orientation as follows: The plasmid pRAJ 162 contains the NPT II gene from the transposon TN 5 inserted as a Sal I fragment and bounded by a polylinker in the plasmid pUC-9 (which was obtained from the Plant Breeding Institute, Cambridge, UK). pRAJ 162 was digested with Hind III and Sma I. The DNA fragment containing the NPT II gene was isolated by elution from an agarose gel. pPAL  001 was digested with Hind III and Sma I and the NPT II gene fragment was inserted. The resultant plasmid was called pPAL 002 and had such orientation of restriction sites and the NPT II gene and nos ter as follows: HIND III, Pst I, Sal I, 3&#39; end NPT II coding sequence 5&#39; end, Sal I, Bam HI, Sma I, Kpn I, Sst I, nos ter, Eco RI. pPAL 002 was cut with Hind III and the site made blunt ended by the use of Klenow fragment. pPAL 0421 was digested with Hinc II and Pvu II, both of which leave blunt ends, and the promoter fragment was ligated into Hind III cut blunt ended pPAL 002. Plasmids were obtained that contained the promoter in both orientations relative to the nos ter signal. One plasmid was chosen with the proper orientation (5&#39; promoter/anti-sense NPT II/nos ter) and was named pPAL 0419. pPAL 0419 has the following DNA fragments: A small (approx. 130 bp) of pGEM 4Z that contains the SP6 promoter, the 550 base pair chimeric promoter, the NPT II gene in the anti-sense orientation relative to the promoter, followed by the nos ter polyadenylation signal. This entire promoter/NPT II/nos ter construct is excisable by Eco RI. pPAL 0419 was digested with Eco RI, and the promoter NPT II nos ter structure was cloned into BIN 19 using the single Eco RI site in the polylinker of BIN 19. The resultant transformation vector was named PAL 1419. In addition to the anti-sense NPT II gene, the vector contains a constitutive NPT II gene under the control of the nos promoter. This vector therefore confers resistance to kanamycin in all cell types with the exception of pollen cells where the gene expression from the constitutive promoter is inhibited by the anti-sense RNA produced from the promoter/NPT II/nos ter construct contained in PAL 1419. 
     In order to provide promoter sequences that could be utilized with additional gene constructs, the plasmid pPAL 0419 was digested with Sal I. This digest removes the NPT II coding region and this Sal I digested pPAL 0149 was religated giving rise to pPAL 0420. pPAL 0420 represents the pollen specific promoter followed by a polylinker for insertion of genes that has the following unique sites: Hinc II, Pst I, Sal I, Bam HI, Sma I, Kpn I, Sst I, followed by the nos ter polyadenylation signal. The entire promoter/polylinker/nos ter construct can be conveniently excised as a single Eco RI fragment. details of this construct is shown in FIG. 7c. 
     Example 4 
     For additional pollen specific promoter constructs, the following approach was used. The intact L4 clone in the lambda cloning vector was digested to completion with the restriction enzymes Sst I and Hha I. The resultant fragments were separated by gel electrophoresis and a 2.65 Kb fragment that contains the promoter/first exon/intron/partial second exon region of gene three in clone L4 and corresponds to nucleotides 4565 to 7210 in the sequence of clone L4 was isolated. This fragment was made blunt ended with Klenow and cloned into the binary transformation vector PAL 1001 previously described. PAL 1001 was first cut with Hind III and made blunt ended with Klenow. Clones containing this fragment (promoter/first exon/intron/partial second exon) were recovered. A clone was chosen that contained this fragment in the proper orientation such that the direction of transcription was towards the nos ter in PAL 1001. This vector was named PAL 1421. This vector contains approximately 1.9 kb of upstream promoter region from the gene 3 in clone L4 followed by the first exon, the complete intron and 15 bases of the second exon of gene three followed by a polylinker containing the following unique sites: Sal I, Xba I, Bam HI, Sma I, Kpn I, SstI, and finally the nos ter polyadenylation signal. A variant of this vector was constructed by digesting PAL 1421 with Eco RI and isolating the fragment from this clone that contains the promoter polylinker nos ter sequences but contained less of the upstream region of the promoter. This fragment was re-cloned into PAL 1009. PAL 1009 is a BIN 19 derived vector from which most of the polylinker has been removed. This vector was constructed by digesting BIN 19 with Hind III and Sst I, making these sites blunt ended with Klenow and relegating such that a vector was recovered that contained a single unique Eco RI site for the insertion of fragments. PAL 1009 was digested with Eco RI and the Eco RI fragment from PAL 1421 that contains a shorter promoter/exon/intron/second exon/polylinker/nos ter structure was added to it. This gave rise to the vector PAL 1422, a vector that is essentially the same as PAL 1421 with the exception that there is less 5&#39; promoter region. It should be noted that both PAL 1421 and PAL 1422 contain the intron from the third gene. For constructs which the presence of the intron may not be desired, intron sequences were removed from PAL 1421 by first digesting PAL 1421 with Eco RI and replacing the promoter/exon/intron/second exon/polylinker/noster structure with the promoter/polylinker/nos ter structure from pPAL 0420 using Eco R1 such that a longer 5&#39; promoter region is reconstructed in the binary transformation vector. The resultant vector was named PAL 1423. The outline of this construction is shown in FIG. 7d. 
     In FIG. 7e, a schematic diagram of the relationship of the above described vectors is presented. It should be noted that the vectors outlined in this Figure fall into three categories: 1, vectors which contain 5&#39; upstream promoter regions that are substantially derived from the upstream region of the gene Bp4C (pPAL 0420, PAL 1420, PAL 1423), 2, promoter constructs that contain 5&#39; upstream promoter regions and intron sequences from the gene Bp4C (PAL 1422, PAL 1421) and, 3, promoters which contain a chimeric 5&#39; upstream region in which a portion of the 5&#39; DNA sequence is inverted relative to the arrangement which appears in the genomic clone and uses the promoter fragment of Bp4A as a core promoter structure (PAL 1107, PAL 1106). It should be noted that the functioning of each of these constructs can vary from plant species to plant species and it may be desirable to test a number of these promoter constructs when carrying out certain aspects of this invention. 
     Example 5 
     The construction of pollen specific vectors that utilize the promoter regions of clones L10 (SEQ. NOS. 5 and 6) and L19 (SEQ. NOS. 7 and 8) was conducted as follows. The construction of the pollen specific vectors depicted in FIG. 8 utilizes promoter regions from clone L10. The start of transcription of clone L10 is located at nucleotide 1. The ATG start codon is located at nucleotides 65-67. The promoter region of this clone was excised by first subcloning the Eco RI-Xba I fragment of the clone that encompasses the entire promoter region and a portion of the first exon (the Xba I site is nucleotide 359 in the DNA sequence). This subclone (pPAL 10EX) was then digested with Hinc II and Nde I. The Nde I site is located immediately upstream of the ATG start codon at nucleotide 62 and the Hinc II site is located at nucleotide number -399. The digestion with these two enzymes releases a DNA fragment of 460 nucleotides which contains 64 nucleotides of untranslated transcribed leader sequence, and 396 nucleotides of 5&#39; promoter region. The Nde I site in this fragment was made blunt ended by the use of Klenow, and this fragment was subcloned into the Hinc II site of the polylinker of pGEM 4Z. Clones were recovered in both orientations and the clone that contained the fragment in the orientation: Hind III, Sph I, Pst I. Hinc II, promoter 64 base pair leader fragment (Nde I blunt/Hinc II, does not cut with either Hinc II or Nde I) Xba I, Bam HI, Sma I, Kpn I, Sst I, Eco RI was chosen and named pPAL 1020. To add additional upstream regions, the Hinc II-HincII fragment that is approximately 1 Kb in length and is immediately upstream of the Hinc II site at position -399 in the DNA sequence was isolated from pPAL 10EX by digestion with Hinc II and gel elution of this fragment. This Hinc II fragment was cloned into the Sma I site of pGEM 4Z. Clones which contained the fragment in both orientations were recovered and a clone that contained the fragment in the following orientation was chosen: Hind III, Sph I, Pst I, Hinc II, Sal I, Xba I, Bam HI, the Hinc II fragment in the same orientation as in the genomic clone, that being right to left,  5&#39;-3&#39; (as a Hinc II/Sma I insertion which does not cut with either enzyme), Kpn I, Sst I, Eco RI. This subclone (pPAL10Hc) was digested with Knp I, made blunt end by the use of Klenow, then digested with Eco RI. To this cut subclone was added the promoter/untranslated leader sequence of pPAL 1020 by digesting pPAL 1020 with Hinc II and Eco RI, and adding this promoter fragment to the cut pPAL 10Hc. The resultant subclone contained a reconstructed promoter region of clone L10 differing from the intact region by only the filled in Kpn I site used for the joining of the two promoter fragments. This construct was named pPAL 1021. This vector contains in the following order: Hind III, Pst I, Sph I, Hinc II, Sal I, Xba I, Bam HI, the approximately 1 Kb Hinc II fragment joined to the Hinc II-Nde I promoter fragment followed by Xba I, Bam HI, Sma I, Kpn I, Sst I, and Eco RI. This subclone allows for the convenient removal of the promoter region of clone L10 such that the promoter can be easily used in cassette transformation vectors. The outline of this construction is shown in FIG. 8. The promoter region of pPAL 1021 was used for the construction of a pollen specific cassette transformation vector by carrying out the following constructs: The plasmid pPAL 1021 was digested with Nco I and Pst I. The plasmid was treated with Klenow and religated. This procedure effectively removed the portion of the polylinker that was 5&#39; to the promoter in pPAL 1021. This plasmid was then digested with Hind III and Sst I, and-cloned into the Hind III and Sst I sites of PAL 1001, giving rise to PAL 1121. PAL 1121 has in the following order: the pollen specific promoter of clone L10 (approximately 1.1-1.2 Kb), followed by a polylinker with the following unique sites: Xba I, Bam HI, Sma I, Kpn I, Sst I, followed by the nos ter. The construction of this is outlined in FIG. 8. 
     Example 6 
     The promoter region of the clone L19 (SEQ. NOS. 7 and 8) as also used for construction of pollen specific vectors. The construction of these vectors is as shown in FIG. 9. Clone L19 has a single pollen specific gene contained with it. The start of transcription in this gene is located at position 1 in the DNA sequence. The ATG start codon is located at nucleotide position 136-138. The only intron is located at nucleotides 1202-1338, the stop translation codon is located at nucleotides 2025-2027. The end of transcription is located at approximately nucleotide 2074. The entire Eco RI fragment of this clone was subcloned into PGEM 4Z by using the Eco RI site located in the polylinker. The resultant clone was named pPAL 1901. The promoter region of this clone was excised as a single fragment by digesting pPAL 1901 with Bam HI and Eco RV, and a 2177 basepair fragment corresponding to the promoter region was isolated. This fragment covers from nucleotide -2022 (Bam HI) to nucleotide 156 (Eco RV). This promoter fragment contains over 2 Kb of 5&#39; upstream region of the promoter in clone L19, 134 basepairs of 5&#39; untranslated leader sequence and 23 basepairs of translated sequence. The Bam HI site in this fragment was made blunt ended by the use of Klenow and cloned into PAL 1001. This step was accomplished by cutting PAL 1001 with Hind III, making this site blunt ended by the use of Klenow and inserting the blunt ended Bam HI-Eco RV fragment in such an orientation that the promoter was oriented 5&#39; to 3&#39; with respect to the polylinker/nos ter polyadenylation signal. This vector was named PAL 1920 and contained within it in the following order: The promoter from clone L19 containing 135 base pairs of 5&#39; untranslated leader sequence, 23 base pairs of translated sequence fused to a polylinker containing a former Hind III site inactivated by blunt ending, Sph I, Pst I, Sal I, Hinc II, Xba I, Bam HI, Sma I, Kpn I, Sst I (the unique cloning sites are underlined), the nos ter polyadenylation signal. This vector is convenient for the insertion of DNA sequences to be transcribed in pollen cells. The outline of this construct is shown in FIG. 9. 
     Example 7 
     This example describes methods used to transform tobacco and Brassica napus. 
     For tobacco transformation, the tobacco cultivar, N. tabacum, cv. Delgold was used. To accomplish this transformation, tobacco leaves less than 8 inches in length were surface sterilized by exposure to ethanol for 5-6 seconds, then subsequent exposure to 1% sodium hypochlorite for a few minutes, usually 5-10 minutes, or until the cut edge of the petiole turned white, then were rinsed several times in sterile distilled water. Leaf segments of approximately 0.5 to 1.0 square centrimeters were excised from the sterile leaves, and were cocultured on shoot inducing media for two days with Agrobacterium tumefaciens GV 3101 carrying the Ti plasmid pMP 90 to provide vir functions in trans (described by Koncz, C. and Schell, J., 1986, Mol. Gen. Genet. 204:383-396) carrying the binary vector of interest. The vector is usually a derivative of Bin 19 which contains the NPT II gene driven by the nopaline synthase promoter and terminated by the nos ter for selection of plant cells with kanamycin. Bin 19 is available from Clonetech Laboratories, Palo Alto, Calif., U.S.A. Transformed tobacco cells are selected on a shoot-inducing medium containing 0.8% agar, MS salts, B5 vitamins, 3% sucrose, 1 mg per L of benzyladenine, 0.1 mg per L of alpha naphthalene acetic acid, (NAA) 300 μg/ml kanamycin and 500 μg/ml carbenicillin (essentially as described by Horsch et al. 1985, Science, 227:1229-1231). Regenerated shoots are then transferred to a root-inducing medium consisting of B5 medium with 2% sucrose, 500 μg/ml carbenicillin and 0.5 mg/L each of NAA and indoleacetic acid (IAA). Rooted transformants are transferred to a misting chamber containing high humidity, after which the humidity is gradually lowered and plants are subsequently transferred to the greenhouse. 
     For transformation of Brassica napus, the binary vector containing Agrobacterium strain GV 3101 carrying pMP 90 to provide vir functions in trans is used. Transformation was carried out either using the method described in Moloney, M. M., et al. (Plant Cell Reports 1989 8:238-242) or, transformation can be carried out with surface sterilized stem epidermal layers. For this procedure, seeds of B. napus L. ssp. oleifera cv. Westar were sown in `Promix` mixed with 2 g/l of the slow-release fertilizer `Nutricoate` in 8&#34; pots. Plants were grown in the greenhouse under a 16 photoperiod (using natural and artificial lighting). For coculture and regeneration experiments stem-sections from the top three stem internodes of approximately 1.5 month old plants were used (i.e. those with elongated floral spikes and several open flowers). Intact stem-sections were surface sterilized for 30 seconds in 70% ethanol and 10 minutes in 1% sodium hypochlorite followed by three rinses in sterile distilled water. 
     For transformation Agrobacterium tumefaciens GV 3101 carrying the Ti plasmid pMP 90 to provide vir functions in trans and the binary vector of choice was grown on YEP media (which consists of 10 gm per L of Yeast Extract, 10 gm per L of Bacto-peptone and 5 gm per L of NaCl , pH 7.0 containing 100 ugs per mL kanamycin for selection of bacterial cells that contained the binary vectors). Cells were grown from one to two days at 28 C. The cells were collected by centrifugation and were resuspended at an approximate density of 10 6  -10 7  cells per mL in liquid EL which consists of MS micro- and macro-nutrients and B5 vitamins containing 40 mg/L of FeNa-EDTA (obtained from BDH chemicals) and 3% sucrose, 10 mg/L BenzylAdenine, and 0.5 mg/L alpha naphthalene acetic acid (NAA) and 18.8 mM KNO 3  plus 20.6 mM NH 4  NO 3 . Medium was solidified with 0.8% agar (Sigma) when the EL media was used for solid media plates. 
     The cell suspension was poured into the bottom of a sterile petri dish and sterilized stems were dissected directly in the bacterial suspensions. The segments were sectioned longitudinally into half segments and cut into approximately 5 mm sections. The dissected segments were placed on filter paper disc on solid EL media for a 3 day coculture under continuous fluorescent light (60 microeinsteins/m 2  /sec 2 ) at 25° C. After a 2-3 day coculture, explants were transferred to solid EL media containing 500 ug/mL carbenicillin, and 100 ug/mL bekanamycin (Sigma). Shoots formed in 4-8 weeks, sections were transferred to fresh solid EL media with carbinicillin and bekanamycin every 3-4 weeks. Shoots that formed and did not bleach were excised and rooted on PDR media (B5- with 2% sucrose and 0.5 mg/L each of NAA and IAA). In some cases, green non-regenerating callus growing on selective medium was separated from explants and transferred to fresh medium to stimulate regeneration. Transformed plants were placed in misting chamber, and after two-four weeks transferred to the greenhouse. Plants were grown under a 16 hour photoperiod and allowed to flower. 
     Clonal propagation was used to increase plant lines as well as hand crossing and selection of seedlings from crossed plants on kanamycin containing media. This media consisted of 0.8% agar, one-tenth MS salts and 100 ugs per mL bekanamycin (available from Sigma Chemicals, St. Louis, Mo., U.S.A.) with no sucrose in the media. Surface sterilized seeds were used. The seeds were surface sterilized by rinsing in 70% ethanol for a few seconds, soaking in 1% sodium hypochlorate for 15 minutes, followed by rinsing three times in sterile distilled water. Seeds were placed on the surface of the agar in sterile dishes and allowed to sprout. Plants which did not carry the kanamycin gene linked to the antisense gene bleached and died, while those that carried the antisense gene stayed green and were subsequently transferred to soil and allowed to flower. 
     Example 8 
     This example describes the isolation of two genes involved in tumour formation in plant tissues following infection with Agrobacterium, the IamS and the IamH genes from the Ti plasmid of the Agrobacterium tumefaciens strain C58. The isolation of the IamH gene is particularly described. The source of DNA coding for these genes was the plasmid pPCV 311. The plasmid pPCV311 is described in: Koncz, C. and Schell, J., Molecular and General Genetics, 1986, 204:383-396, and contains the oncogenic region of the T-DNA plasmid contained in the C58 strain of Agrobacterium. The plasmid pPCV 311, contains a region of T-DNA that when transferred to plant cells causes tumour formation. This oncogenic region of the T-DNA is entirely contained in the plasmid pPCV-311. This region of DNA contains four genes, that when expressed in plant cells are sufficient for tumour formation. The approximate coding regions of these four genes and the direction of transcription of these four genes are indicated in FIGS. 4A and 4B. The other portions of the vector pPCV 311 are not shown in that they are not relative to the following constructions. Additionally, the oncogenic region of the Agrobacterium strain C58 is located on the T-DNA plasmid within that bacterium, commonly referred to as the wild-type nopaline plasmid. A nearly identical oncogenic region is also found in wild type octopine strains which could also be used as a source of genes. The complete nucleotide sequence of an octopine strain oncogenic region is described by Barker et al., Plant Molecular Biology 2:335-350 (1983). The partial sequence obtained from various constructs of genes derived from pPCV 311 was compared to the published nucleotide sequence. 
     Two genes were isolated from pPCV 311, the IamH and the IamS genes, commonly referred to as genes 2 and 1 respectively. The IamH gene was isolated by first subcloning the indicated Hind III fragment, a fragment that contains all of the coding region of gene 2 and additional 5&#39; sequences that were subsequently removed for the construction of a promoterless version of the gene. The restriction sites mapped in this subclone are shown in FIGS. 4A and 4B and the subclone is referred to as pPAL G2. For the isolation of coding sequences only, pPAL G2 was first split into two smaller clones and the gene later reconstructed. The Xba I-Sma I and Sma I-Sma I fragments shown in FIGS. 4A and 4B were isolated by gel elution and subsequently cloned into the following vectors: The Sma I-Sma I fragment was cloned into pGEM 4Z, giving rise to pPAL 899. The Xba I-Sma I fragment was subcloned into pGEM 7Z, giving rise to pPAL 898. The 5&#39; non-coding sequences of the IamH gene that are present in this subclone were removed in the following fashion: pPAL 898  was digested with Eco RI, the Eco RI site is in the promoter region of the clone, and in this subclone is the only Eco RI site. This digested DNA was then treated with Exonuclease III, and following digestion treated with S1 nuclease and the Klenow fragment of DNA polymerase I. The treated DNA was then cut with Pst I and treated with Klenow fragment in order to make the Pst I site blunt. The linear, digested, blunt ended plasmid was then relegated and used to transform E. coli DH5-alpha according to standard protocols. Subclones were chosen, sequenced and one subclone was chosen that was deleted to 8 nucleotides in front of the ATG start of translation codon. The ATG start codon was determined by comparison of the nucleotide sequence obtained from the deleted subclones to the nucleotide sequence for the octopine strain described by Barker, et al. Plant Molecular Biology 2:335-350 (1983). The nucleotide sequences of both the 5&#39; non-coding and the coding region were nearly identical. This subclone was named pPAL 897, the ATG codon is shown in FIGS. 4A and 4B, the direction of transcription in this case would be from right to left in FIGS. 4A and 4B. The plasmid contained the 5&#39; half of the coding region from the IamH gene, with the promoter sequences deleted. 
     The construction of the 3&#39; half of the lamH gene, contained in the plasmid pPAL 898 was carried out as follows. A 3&#39; region of the gene that contains the polyadenylation signal naturally found in the gene was isolated by digestion pPAL 898 with the enzymes Bam HI and Apa I. The digested DNA was treated with Klenow fragment to make it blunt ended and was religated. This gave rise to the subclone pPAL 896, which is a plasmid that contains the 3&#39; half of the IamH gene. To reconstruct the intact lamH gene, pPAL 896 was digested with Hind III and Sma I, and the 3&#39; half gene fragment was isolated by gel elution. pPAL 897 was digested with Sma I and Hind III and the isolated 3&#39; fragment from pPAL 896 was cloned into these sites, reconstructing a promoterless version of the gene that contains the indicated array of restriction sites flanking the gene. This plasmid was named pPAL 895 and is shown in FIGS. 4A and 4B. 
     Example 9 
     This example describes the isolation and construction of a promoterless version of the gene 1, IamS: indole acetamide synthase gene of the Ti plasmid of the Agrobacterium tumefaciens strain C58 which procedure is summarized in FIG. 3. The gene was isolated from the plasmid pPCV311. The Sma I-Pst I fragment that contains 5&#39; and 3&#39; regions of the lamS gene as well as the coding region was isolated by gel elution and subcloned into a derivative of pGEM 4Z called pGEM-noEco. pGEM-noEco is a plasmid from which the Eco RI site of pGEM 4Z has been removed by cutting with Eco RI and making blunt ended and relegating such that only the Eco RI site was removed. The fragment was inserted in the orientation shown relative to the polylinker. This subclone was called pPAL 889. pPAL 889 was digested with Eco RI, and briefly treated with Exonuclease III, followed by S1 nuclease. The DNA was digested with Sma I and treated with Klenow fragment to make it blunt ended. The DNA was relegated and clones recovered. Some of these clones were chosen, sequenced, and one clone was found which had 5&#39; sequences deleted such that only approximate 15 bases upstream of the ATG start of translation codon remained. This plasmid was named pPAL 888. The Kpn I site at the 5&#39; end of the gene as well as the Pst I site at the 3&#39; end of the gene were both converted to Sal I sites by cutting with Kpn I, end filling with Klenow and adding synthetic Sal I linkers, and repeating the linker addition at the Pst I site such that the entire gene can be excised as a single Sal I fragment. This plasmid was named pPAL 887. This plasmid contains the promoterless version of the lamS gene and contains the array of restriction sites shown that flank the gene as shown in FIG. 3. 
     Example 10 
     In this example, a pollen specific promoter is used to synthesize the enzyme IamH specifically in pollen cells. The enzyme has activity that can cause the production of NAA from NAM, the substance NAA functioning as a plant hormone that is substantially toxic to developing pollen grains, while the precursor NAM being relatively non-toxic. For this example, the IamH gene was inserted into the vector PAL 1423. The IamH gene was isolated from pPCV311 as described in FIGS. 4A and 4B and cloned as a Sal I fragment in the Sal I site of PAL 1423, creating PAL 1426. This vector has the IamH gene (T-DNA gene 2) under the control of a pollen specific promoter from clone L4 in the sense orientation. PAL 1426 was used to transform Tobacco as outlined in Example 1. 
     Example 11 
     In this example, we use a pollen specific promoter to synthesize the enzyme IamH specifically in pollen cells. The enzyme has activity that can cause the production of NAA from NAM, the substance NAA functioning as a plant hormone that is substantially toxic to developing pollen grains, while the precursor NAM being relatively non-toxic. For this example, the IamH gene was inserted into the vector PAL 1423. The IamH gene was isolated from pPCV311 as described in FIGS. 4A and 4B and cloned as a Bam HI-Sst I fragment in the Bam HI-Sst I sites of PAL 1423, creating PAL 1424. This vector has the IamH gene (T-DNA gene 2) under the control of a pollen specific promoter from clone L4. PAL 1424 was used to transform Tobacco as outlined in example 1. 
     Example 12 
     In this example, two isogenic plant lines (A1, A2) were produced that carried either the IamS or the IamH genes. Tobacco plants were transformed with PAL 1426 containing the IamH gene as in Example 4, producing the A2 line. The IamS gene described in FIG. 3 was inserted as a Sal I fragment into the vector PAL 1423 in the sense orientation, giving rise to PAL 1425. PAL 1425 was used to transform tobacco as described and tobacco plants were produced that carried PAL 1425. These lines represented the A1 lines. Tobacco plants that contained both PAL 1426  and PAL 1425 were selfed and homozygous A1 and A2 lines were selected. 
     Example 13 
     In this example, PAL 1426 (see Example 10) and PAL 1425 were used to transform Brassica napus. Plants lines homozygous for the A1 and A2 genes were selected as in Example 6. 
     Example 14 
     In this example, tobacco pollen was harvested from control tobacco plants and from tobacco plants transformed with gene 2 of Agrobacterium tumefaciens, namely the IamH gene, as described in Examples 1 and 10, using PAL 1426. The pollen was then germinated in vitro on matrices containing either NAM or NAA in various concentrations. 
     In reference to Table 2, pollen from neither the control plants nor the transformed plants germinated in the presence of NAA, which is cytotoxic. The data shown in Table 2 is expressed as the percentage of pollen grains that germinated. 
     Both control and transformed pollen germinated in the absence of NAA and NAM. 
     In the presence of NAM, the germination of pollen from control plants was only inhibited at the highest concentration tested (50 ug/ml). By contrast, the germination of pollen from transformed plants was significantly inhibited at all concentrations of NAM tested. Furthermore, pollen tubes that did develop were less than 20% of the length of pollen tubes formed under control conditions. This indicates that the IamH gene is being expressed and that the gene product IamH is functional in transformed plants. 
     The present invention has been described in detail and with particular reference to the preferred embodiments; however, it will be understood by one having ordinary skill in the art that changes can be made thereto without departing from the spirit and scope thereof. 
     
                                           TABLE 1                                 
__________________________________________________________________________
Transient Male Sterility                                                  
            Plant Line                Plant                               
Actuating Agent                                                           
            A2                        A1                                  
__________________________________________________________________________
non toxic   psp + IamH                cp + IamS                           
substance   psp + IamH                psp + IamS                          
inducing    psp + IamH and ip + IamS  psp + IamS                          
molecule    psp + IamH and ip + IamS  cp + IamS                           
            ip IamH and psp + IamS    psp + IamH                          
            ip IamH and psp + IamS    cp + IamH                           
toxic       cp + crg + psp + anti-sense to crg and psp + IamH             
                                      psp + IamS                          
molecule    cp + crg + psp + anti-sense to crg and psp + IamH             
                                      cp + IamS                           
            cp + crg + psp + anti-sense to crg and cp + IamH              
                                      psp + IamS                          
__________________________________________________________________________
 Notes: psp = pollen specific promoter; cp = consitutive promoter; ip =   
 inducible promoter; + = A plus sign between a specified promoter and a   
 specified gene indicates that the promoter regulates the expression of th
 specified gene; crg = a gene conferring a chemical resistance.           
 
    
     
                       TABLE 2                                                     
______________________________________                                    
NAA                                                                       
concentration (μg/ml)                                                  
                   NAM concentration (μg/ml)                           
Plant  0      12.5   25   50   0    12.5  25   50                         
______________________________________                                    
501    100    0       1*  0    100   45*   10* 0                          
503    100    0      0    0    100   70*   36* 0                          
507     84    0      0    0     84   2.5*  0   0                          
508    100    0      0    0    100  51     0   0                          
Control                                                                   
        82    0      0    0     82  65    72   0                          
______________________________________                                    
 *pollen tubes were less than 20% of control length                       
 
    
     
         __________________________________________________________________________
SEQUENCE LISTING                                                          
(1) GENERAL INFORMATION:                                                  
(iii) NUMBER OF SEQUENCES: 10                                             
(2) INFORMATION FOR SEQ ID NO:1:                                          
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 3293 base pairs                                               
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: double                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: DNA (genomic)                                         
(ix) FEATURE:                                                             
(A ) NAME/KEY: CDS                                                        
(B) LOCATION: join(3..125, 690..1796, 1913..2209)                         
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:                                   
GAATTCCTCAACANNTGATTCTCATCAACGGACAGTTCCCTGGTCCT47                         
IleProGlnXaaXaaIleLeuIleAsnGlyGlnPheProGlyPro                             
1 51015                                                                   
AACCTAAACTCCACATCCAACAACAATGTCGTCATCAATGTTTTCAAC95                        
AsnLeuAsnSerThrSerAsnAsnAsnValValIleAsnValPheAsn                          
 202530                                                                   
AACCTTGACGAGCCTTTCCTCTTGACCTGGTTAGTCACCATTTCCTCTCA145                     
AsnLeuAspGluProPheLeuLeuThrTrp                                            
3540                                                                      
TT TTATAGGCATTCTGTTTCTAAAATTTAAATGATATTTTAAAGCTACAATTTTTTTTTC205          
ATTTTTAATATAACTGTTCTTTTACAAAGGCCAAACGAGAAATGCAAATGGAAAGTTCTC265           
ATTTCGTTTGATATTTTCATTTACAGTTAACATATGATTTTTTTTTTC AGATCTTTGTAG325          
GTTTGTTTGAAAAAAGTTTTGGTATAGTTATGTTATTTTGTTTCCTGGATCTTAGGTTTG385           
AATAATTCATAACCAAATTGAAAACAAAAACTTTTGGATCGTTAATCAAATCTTCTTCTT445           
ATTTTTTAAATGTTATATTAATTTC ACATAATTACATCTATATATAATATATAAATACAA505          
ATAAAATGATAATTTCAGTTTATCATATATTAAATCAGACTAAAATAATAAAAACAAAAA565           
GAAATTTAAACACATTTTGACTCAGTTTTAGATTAAGATTGGTTATATTACCACAAGTAA625           
TT ATGCTAGTCTTCATTGCAAATTTAAACACATTTTAACTATGTGGGTTCGGTGACATGG685          
CAGGAGTGGTCTCCAGCACAGGAAGAACTCATGGCAAGATGGTGTGACC734                      
SerGlyLeuGlnHisArgLysAsnSerTrpGlnAsp GlyValThr                            
455055                                                                    
GGAACCTCATGCCCAATCCCAGCAGGCACCAACTACACTTACCATTTC782                       
GlyThrSerCysProIleProAlaGlyThrAsnTyrTh rTyrHisPhe                         
606570                                                                    
CAGCCTAAGGACCAGATCGGTAGCTACTTCTACTACCCATCAACCGCC830                       
GlnProLysAspGlnIleGlySerTyrPheTyrTyrProS erThrAla                         
758085                                                                    
CTGCACCGTTTCTCCGGTGGTTTCGGTGGCCTCCGTGTCAACAGCCGT878                       
LeuHisArgPheSerGlyGlyPheGlyGlyLeuArgValAsnSer Arg                         
9095100                                                                   
CTCCTCATCCCCNTCCCTTACGCTGACCCCGAAGATGACCACACCATC926                       
LeuLeuIleProXaaProTyrAlaAspProGluAspAspHisThrIle                          
105 110115120                                                             
CTCATCAACGACTGGTACACCAAGAGCCACACCGCTCTCAAGACCTTC974                       
LeuIleAsnAspTrpTyrThrLysSerHisThrAlaLeuLysThrPhe                          
 125130135                                                                
CTTGACAGCGGCCGCACTCTTGGTTCCCCTGACGGTGTCCTCATCAAC1022                      
LeuAspSerGlyArgThrLeuGlySerProAspGlyValLeuIleAsn                          
 140145150                                                                
GGAAAGTCCGGTAAAGTCGGAGGACAAAACAAGCCTCTCTTCACCATG1070                      
GlyLysSerGlyLysValGlyGlyGlnAsnLysProLeuPheThrMet                          
 155160165                                                                
AAGCCAGGAAAGACCTACAAGTACAGAATCTGTAACGTTGGGTTCAAA1118                      
LysProGlyLysThrTyrLysTyrArgIleCysAsnValGlyPheLys                          
170 175180                                                                
TCCACTCTTAACTTCAGGATCCAAGGACACAAGATGAAGCTTGTTGAG1166                      
SerThrLeuAsnPheArgIleGlnGlyHisLysMetLysLeuValGlu                          
1851 90195200                                                             
ATGGAAGGATCTCACGTTCTCCAGAACGACTACGACTCGCTCGACGTC1214                      
MetGluGlySerHisValLeuGlnAsnAspTyrAspSerLeuAspVal                          
 205210215                                                                
CACGTCGGACAGTCGTTCGCTGTTCTTGTGACCGCTGACCAAGAGGCC1262                      
HisValGlyGlnSerPheAlaValLeuValThrAlaAspGlnGluAla                          
220 225230                                                                
AAGAGCTACTACATGGTTGCATCCACTAGGTTCCTCAAGAAGGAAGTG1310                      
LysSerTyrTyrMetValAlaSerThrArgPheLeuLysLysGluVal                          
235 240245                                                                
AGCACTGTTGGTGTGATGAGCTACGAAGGAAGCAATGTTCAGCCTTCA1358                      
SerThrValGlyValMetSerTyrGluGlySerAsnValGlnProSer                          
2502 55260                                                                
AATGTGCTTCCCAAGGCTCCAGTTGGATGGGCTTGGTCTCTTAACCAG1406                      
AsnValLeuProLysAlaProValGlyTrpAlaTrpSerLeuAsnGln                          
265270 275280                                                             
TTCAGATCATTCAGATGGAACTTAACCGCCAGCGCGGCTAGGCCTAAC1454                      
PheArgSerPheArgTrpAsnLeuThrAlaSerAlaAlaArgProAsn                          
285 290295                                                                
CCGCAAGGATCTTACCATTACGGAAAGATCAACATCACACGTACCATC1502                      
ProGlnGlySerTyrHisTyrGlyLysIleAsnIleThrArgThrIle                          
300 305310                                                                
AAGCTCGCCAACACCAAGAACTTGGTGGACGGTAAGGTCAGGTTTGGG1550                      
LysLeuAlaAsnThrLysAsnLeuValAspGlyLysValArgPheGly                          
315320 325                                                                
CTTAACGGTGTATCACACGTTGACACCNAGACTCCCTTGAAGCTTGCT1598                      
LeuAsnGlyValSerHisValAspThrXaaThrProLeuLysLeuAla                          
330335 340                                                                
GAGTACTTCNAGATGTCCGAGAAGGTCTTCAAATACAATGTCATCAAG1646                      
GluTyrPheXaaMetSerGluLysValPheLysTyrAsnValIleLys                          
345350355 360                                                             
GACGAACCAGCAGCCAAGATCACTACACTAACCGTTGAGCCTAATGTC1694                      
AspGluProAlaAlaLysIleThrThrLeuThrValGluProAsnVal                          
365370 375                                                                
CTTAACATCACTTTCCGTACCTTTGTTGAAATCGTCTTCGAGAACCAC1742                      
LeuAsnIleThrPheArgThrPheValGluIleValPheGluAsnHis                          
380385 390                                                                
GAGAAGAGCATGCAATCATTCCATTTGGATGGTTACTCCTTCTTCTCA1790                      
GluLysSerMetGlnSerPheHisLeuAspGlyTyrSerPhePheSer                          
395400 405                                                                
GTCGCGTAAGCTTCATTAATAACTCTATAGGCCAATGTTTCACTTANTANGCGCAG1846              
ValAla                                                                    
410                                                                       
AACCGGCGTGATCTTTTACTTCAGATATAAGATTCCTAACAATTTTTTTAATATTTTTTC1906          
AACAGTTCTGAGCCAGGAACA TGGACACCAGAGAAGAGAAACAACTAC1954                     
SerGluProGlyThrTrpThrProGluLysArgAsnAsnTyr                                
415420                                                                    
AACTTGCTCGATGCGGTCAGCAGACACACC GTGCAAGTNTTCCCCAAG2002                     
AsnLeuLeuAspAlaValSerArgHisThrValGlnXaaPheProLys                          
425430435440                                                              
TCGTGGTCCGCCATCCTCTTGACATT CGACAACGCCGGTATGTGGAAC2050                     
SerTrpSerAlaIleLeuLeuThrPheAspAsnAlaGlyMetTrpAsn                          
445450455                                                                 
ATCAGATCAGAGAACTGGGAGAGAA GATACTTGGGACAGCAAATGTAC2098                     
IleArgSerGluAsnTrpGluArgArgTyrLeuGlyGlnGlnMetTyr                          
460465470                                                                 
GTCAGTGTTCTTTCCCCTGAGAAATCA CTAAGAGACGAATACAACATC2146                     
ValSerValLeuSerProGluLysSerLeuArgAspGluTyrAsnIle                          
475480485                                                                 
CCACTCAACACCAACCTTTGTGGTATCGTTAAG GGCTTGCCATTACCT2194                     
ProLeuAsnThrAsnLeuCysGlyIleValLysGlyLeuProLeuPro                          
490495500                                                                 
ACACCCTACACTATTTAATTAAACTCACTTCCACAAAAGTTTTATT TATTTATTT2249              
ThrProTyrThrIle                                                           
505                                                                       
GATATATGTAAAATTCTACTTTTTACAAGTGAGTGTATTACGTGACTAATTAACCCTTTC2309          
CTAATTTCATTTAACATACTACTACTATAATTACAGATCCCATTGTTGTTTCACTAATAG2369          
TAA TATATACAACATTTAGCTTACTTAATATAATCCTGATTCTAACACAAAAGACTGTTA2429         
TTCATTTCATAATGAACAAAACTTGTTCACCCCCTATGGTGAACCCTCTAATTCACCTCT2489          
ATTCTTAACACCAATCAAATTGACATGTAAGATTAATAAAAAAAGAAAT AAAATTTAAAA2549         
GAAAAAAATAGGTTTCCTAAAAAAGGGTTTATTTGTCAAATAACCAAAAAAAAATGAAAA2609          
TTANATTTTGGGAGAGAGAGTAGAGAGAGATAGGAANAAAAAGTAGGAGAGAGGAGAGAA2669          
TTTTAGTTAGTTAGTGTATTTAAGTT TTTTTCATGTATATAGGGTGCAATTTCCCAAAAA2729         
AAAAAGTCTCGGTTAACAAGGAAAATAACGTGTGTTTTGTTACGCCGTCCATCGACGTCT2789          
TCTTCTTTATAGCCCAGAGAAGATAGAAAGCTGAGTCTCCAGTTCTATGCTTCCAAATCA2849          
AAT TTCGATTTCATCTTCTCCAAATCAAATCAAGCCATGTTGCCTTATGAGTAGAAAGAG2909         
CGCTGATGGTGGAGATGAAGATGATGGTATGGGATTCAAACTTGCAGGCCCCAGGGAGGA2969          
AGAAGATGACTTTACTTGTGAACCAGNCTGTGCCTAAAATTCAACAAAA GAAACCGATGG3029         
CAATTGGAAATCAGACACTACAACTTGNTTAAATAAAAACGCTANTTGTAATGTATTCTT3089          
AGAATATAGACTTGCAAGTTGATGAGAACTCACTGATGCAAGTGTCGTGATCTTTGATGT3149          
AGTAAGGTCACAGCAACAGACTTTTA ATGTATTCTTAAAATATAGATTTGCAAGTTCTTT3209         
GTTGTATTTCTTCTTCTTCGTGGGACATCTGACCTGTAAATCAGAGATATAATCCCACCA3269          
AACCCAAGGTTTCCTGGTTTAATT3293                                              
(2 ) INFORMATION FOR SEQ ID NO:2:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 509 amino acids                                               
(B) TYPE: amino acid                                                      
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: protein                                               
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:                                   
IleProGlnXaaXaaIleLeuIleAsnGlyGlnPheProGlyProAsn                          
15 1015                                                                   
LeuAsnSerThrSerAsnAsnAsnValValIleAsnValPheAsnAsn                          
202530                                                                    
LeuAspGluProPheLeuLeuThrTrpSerGly LeuGlnHisArgLys                         
354045                                                                    
AsnSerTrpGlnAspGlyValThrGlyThrSerCysProIleProAla                          
505560                                                                    
GlyThrAs nTyrThrTyrHisPheGlnProLysAspGlnIleGlySer                         
65707580                                                                  
TyrPheTyrTyrProSerThrAlaLeuHisArgPheSerGlyGlyPhe                          
 859095                                                                   
GlyGlyLeuArgValAsnSerArgLeuLeuIleProXaaProTyrAla                          
100105110                                                                 
AspProGluAspAspHisThrI leLeuIleAsnAspTrpTyrThrLys                         
115120125                                                                 
SerHisThrAlaLeuLysThrPheLeuAspSerGlyArgThrLeuGly                          
1301351 40                                                                
SerProAspGlyValLeuIleAsnGlyLysSerGlyLysValGlyGly                          
145150155160                                                              
GlnAsnLysProLeuPheThrMetLysProGlyLysThrTyrLysTyr                          
 165170175                                                                
ArgIleCysAsnValGlyPheLysSerThrLeuAsnPheArgIleGln                          
180185190                                                                 
GlyHisLysMe tLysLeuValGluMetGluGlySerHisValLeuGln                         
195200205                                                                 
AsnAspTyrAspSerLeuAspValHisValGlyGlnSerPheAlaVal                          
210215 220                                                                
LeuValThrAlaAspGlnGluAlaLysSerTyrTyrMetValAlaSer                          
225230235240                                                              
ThrArgPheLeuLysLysGluValSerThrValGlyV alMetSerTyr                         
245250255                                                                 
GluGlySerAsnValGlnProSerAsnValLeuProLysAlaProVal                          
260265270                                                                 
 GlyTrpAlaTrpSerLeuAsnGlnPheArgSerPheArgTrpAsnLeu                         
275280285                                                                 
ThrAlaSerAlaAlaArgProAsnProGlnGlySerTyrHisTyrGly                          
290 295300                                                                
LysIleAsnIleThrArgThrIleLysLeuAlaAsnThrLysAsnLeu                          
305310315320                                                              
ValAspGlyLysValArgPheGlyLe uAsnGlyValSerHisValAsp                         
325330335                                                                 
ThrXaaThrProLeuLysLeuAlaGluTyrPheXaaMetSerGluLys                          
340345 350                                                                
ValPheLysTyrAsnValIleLysAspGluProAlaAlaLysIleThr                          
355360365                                                                 
ThrLeuThrValGluProAsnValLeuAsnIleThrPheArgThrPhe                          
 370375380                                                                
ValGluIleValPheGluAsnHisGluLysSerMetGlnSerPheHis                          
385390395400                                                              
LeuAspGlyTyrSer PhePheSerValAlaSerGluProGlyThrTrp                         
405410415                                                                 
ThrProGluLysArgAsnAsnTyrAsnLeuLeuAspAlaValSerArg                          
420 425430                                                                
HisThrValGlnXaaPheProLysSerTrpSerAlaIleLeuLeuThr                          
435440445                                                                 
PheAspAsnAlaGlyMetTrpAsnIleArgSerGluAs nTrpGluArg                         
450455460                                                                 
ArgTyrLeuGlyGlnGlnMetTyrValSerValLeuSerProGluLys                          
465470475480                                                              
Ser LeuArgAspGluTyrAsnIleProLeuAsnThrAsnLeuCysGly                         
485490495                                                                 
IleValLysGlyLeuProLeuProThrProTyrThrIle                                   
500 505                                                                   
(2) INFORMATION FOR SEQ ID NO:3:                                          
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 8585 base pairs                                               
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: double                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: DNA (genomic)                                         
(ix) FEATURE:                                                             
(A) NAME/KEY: CDS                                                         
(B) LOCATION: join(308..370, 1136..1261, 6369..6428,                      
7198..7353)                                                               
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:                                  
GAATTCTAAAAATAGCAATAACTTTTTGAGAACATCAGATTTATGTACACGCATAGGACA60            
CATACCTTTTTATTTACTTAAAGGAAAATGAACGAGTCTAAATCTTCCACATGTTATATG120           
AGCAAAACATGAATTTTTCTAAATTAGATTC GTTTAAATCAGAACATATTAATGTGAGTT180          
TCTTAAATTAGATTTTTAATATCTATATATACGTAAGAATACTTCTTATGTTTTAAAATA240           
AAAAATAGAATACTTCATCTCTTTCCTAAATTTTTAAGCCAATATCAATCCATTTCTATA300           
ATCTAAGA TGAAGAAATCCCTTCAACTCTCTTTTTCGTTCTTAATTATC349                     
MetLysLysSerLeuGlnLeuSerPheSerPheLeuIleIle                                
1510                                                                      
TCCATCATTCTCTCA CATGGTTTGTATTTTCATCTTAATATATTGCATATA400                   
SerIleIleLeuSerHisGly                                                     
1520                                                                      
GTAATTCCATAATAAATTGATTATACTAAAATTTGACTTTTAAAATATTGTCAACCCCCA460           
TATAATAAATTTTAT TTACTATATAAAACATAGCATTAAATTATCTCTTTGTGTAAAATT520          
CATAACTTTGCAGAAGGCTAGAAAATATAGATAGTATAGTCAGAAATGTTTGCGTTAAAA580           
TTGAAAGGATCAACCATGGAGTATTTAAATGTTTTTTATACTTTATGCCATTTATAATTT 640          
TTTTAATGTATGGGTTTATATATGATGAAGAACTATTATGATAAAATAATATTAAATAAT700           
TTCATTTTTATCATCTATTTATGAACATTTTGTCCTGCACATACAAATGATTTAACCAAC760           
ATTTTTAATAATATGGATGAACTATAGCTCTTACGTAA ATTTATTTGATATTTTTAATTA820          
AATTTATATATTTTTATAGGTAATTTGTTATGCTTTTCCAATACATACAGTAGTTGTTAT880           
TAAAATATCAAAATTTAATACGTAATGTTTATTAATATGCACACAATTCTTAAAACCATA940           
TTTTTAAAAAATAAT GTGTGACCAAACGATATGCTCATTTTTTTATTTACTAGCAAAATA1000         
TATTTCTTTTCTTACTTATAACGTTTAAAAAGAAATGTTATTAAACATTTTTTGCTGATA1060          
AATAAATTTTATATTTCATAAAATCTAAATATATTTTTTAACAATTAAAATTTGAAATTT 1120         
TTATATCTTACAGGAATGATGGCAGATGCGCAGAAAAAGAATTGTCCTCAT1171                   
MetMetAlaAspAlaGlnLysLysAsnCysProHis                                      
253 0                                                                     
AAAATTCCAATAAAAGGAAGTTATTGTGCTCCAACTATATGTTTGGAT1219                      
LysIleProIleLysGlySerTyrCysAlaProThrIleCysLeuAsp                          
354045                                                                    
ATGTGT AAGAAGCAACATGGAACTGTTGGTAGTTGTGCGGAA1261                           
MetCysLysLysGlnHisGlyThrValGlySerCysAlaGlu                                
505560                                                                    
TAAAAATGATTTTGTAACTGCGCTTGTA AGTAAGGGTTCTCACTAAGTGTTATGAATCTA1321         
GTAATGTCCAACCAAAGTTTTATATTATTTCTTTTAACAATAAGTCTAAATGTTTGTCTC1381          
AGATTTGTGGATCTATTTATAATAAATAATAATATGAATGTTAAATAAATACAAATGTGT1441          
AAAAC AAGAGTGGACTATTAATAAAATATATGATTACATTATTGTTAGAAGTAACCAATA1501         
TTACGTGTAAAATCAAAATCTTAAGACAAGTTAAAAAGATTGAGATGAAATCACAACCAA1561          
TATTTAAATGTGAGATAATCAACTAACATGTAATTTTGTACACATTGTAA AAAAAAAAAA1621         
GCAAGAGTTCATTATCAAACAAGAAAGTGTTAGAAAGAGCAACAGATTCATTGCAAGGGC1681          
AGTCTAGGTTGAATTGGCTTGACATAGGGAAAATTGAAAGCACTGTTTCTGAACATGACA1741          
ACGCTTGGTCAGGAAGAACAATCTCACA ACCAGAGTTTTGGGTAGATTTCTCCAATGTCA1801         
TTATCAGGTACGAGTTATGAGACTTCATCCACATCTCAGTCCCAGTTCCCTTCTCAGGAA1861          
GTTTCCTTGAGGAAGGAGGTTATTACAGAAAGCTAAGTTACATGAGCCTGACATATCATG1921          
CAAGG GCAGTCCCAACAAGAAAATGTTAGAAAGAGCAACATATCATGCAAGGACAGTCCA1981         
GGTTTGAATTGGCTTGACAGATGGTTTGCAGACATGCCATCTGAAGGTCCTACAAACTCA2041          
TCAGACAACGAAGGAAAATTGATAGCATTGTTTCTGAACATGACAAAACT CTAGTCAGGA2101         
AGAAGAATCTCACAACCAAAGTTTTGGGTAGAGCTCCTCCAATGTCATCATCAGCTACGA2161          
GTTCAAAGACTTCATCCACATCTTAGTCCCCATTCTCTTCTCATGAAGTTTCCTTTAGGA2221          
AAGAGGTTATTACAGAAAGCCAAGTTAC ATGAGCCTAACACAATCTATCAAAGCTAAGAA2281         
GAGACGATTAACCATTATTCTTCATCTTTTTGTCCCAAAATCACTGTTTGAAAAGAAACA2341          
GTCCATGTCTTACAACGAAGATGTGAATGTAAAGCGTTGTGCATGTTCGGATCCATCTTG2401          
CAACC AGCAGAGTTATCTATATCCACATGCTCAAGTAACAAGGAAAAATATGTGGGCAAA2461         
GAAGGTAAAGTGAACATCGTTTCATTAATTCATTAAAGCATTTCAACACCTTGATGGTTC2521          
TAAATACACACAAAACACTGATTTATAGATACATAAGCAACTTCTGTGTA TGTTCTTTTA2581         
CATACAAGTTGGTATCAAGGCTGTTGCAATGTTGTTGTTTGACCACTTTTATTATTTAAT2641          
AGTTAACTTTTGATGCTTCTAAGATAATATGTTCCTCCTAACTCTTGTCAACATGAAAGA2701          
CCAATTAAAGGTTTTGATTAAATACATA CTAATTTTTTAATATAATCTTATAAGTTATGT2761         
TACGTGTGGGACATCCACCTAATAAACTATAAATTTAAATAATAATGTTTGAAAAGGATT2821          
TTATTGACATTCCTTTAAATAAATTCATAATTTTAAAAATAGCGATAACTTTTTGAAAAC2881          
ATCAG AATTATGTACACGCAGAGGACACATACCTTTTTATTTACTTATAGGAAAATGAAC2941         
GAGTCTAAAGCTTCCACATGTTATATGAGCAAAACATGGATTTTTCTAAATTAGATTCGT3001          
TTAAATCAGAACATATTAATGTAAGTTTCTTAAATTAGATTTTTAATATG TATATATATG3061         
TAAAAATACTTCTTTTTTTTTTTTTTGTCATCAGCATTACAGATTTCTAAATAAGTTACT3121          
TCTTATGTTTTAACAAATAGAATACTTCATCTCTTTCCTAAATTTTAAGTCAATATCAAT3181          
CCATTTCTATAATCCGAAGATGAAGAAA TCCCTTCATCTCTAGAAAATAGGGTCAGAAAG3241         
TTTTGCGTTAAAATTGAAAGGATCATCCCTGAAGTATTTATTTGTTTTTTTTATGCTTTA3301          
GTCCATTAATATTTTTTTAATGTATGGGTTTATATATGATTAAGAACTTCCATGATAAAA3361          
TAATA TTAAATAGTTTTATTTCTTATCATCTATTTATGAACGTTTGTTCCTGCACACACA3421         
AATGATTTAACCAACATTTTTCATAATATGGATAAACTATAGTTCTTATGTAAATTTATG3481          
TGATATTTTAATTAGATTTATATATTTATAGGTAATCTATTATGCTTTTC CAATACATAC3541         
AGTAGTTGTTCTTAAAACATCAAATTTTTATATGTAATGTTTATTAATATGCACACAATT3601          
CTTAAAACAATATTTTCACAACATAAAAAAATAATGTTTGACCAAACCATATGCTCATTT3661          
TCTTTATTTACCGGCAAAAACCATTTCT CCATTTTTTTACTTATAACGCTTAAGATAAAA3721         
AAATTATTAAACAGTTTTTGTTGATAAATAAGTTTTATATTTCAGAAAATGTATTATATT3781          
TTCAAACAATTAAAATTTGGGTTTTTATATCTAACATAAATGATGGCAGAAGCACAGAAA3841          
AATAA TTGTCTTCATAAAATTCCAATAAAAGGAAGCTAGTGCATTCCAAATAAATGTTTG3901         
GCTATGTGTAAGAAGCAACATGGAACTCTTGGTAGTTGTCCGGAAAAAGAAATTTGTAGT3961          
TGTGCTTGTAAGTAAGGGTTCTCACTAAGTGTTATGAATCTAATAATGTC CAACCAAAGT4021         
TGTATATAATTTTTTAACAATAAATGTCTAAATGTTTGTCTCAGATTTGTGGATCTATTT4081          
ATAATAAATAATAATATGAATGTTAAATAAATACAAATGTGTAAAAAAAGATTGGACTAT4141          
TAATAAAATAAATGATCACATTATTATT AGATGTAACCAATATTGTGTATAAGATCGTAA4201         
AAGCTTAAGACGAGTTAAAAAGATAGAGATGAAATCACATCCAATATCTAAATGTGAGAT4261          
AATCAACTAACATATAATTTTGTATATATTGTAAGATAAAATAAAAATAAAAATTAAAAA4321          
GCAAG AGTTGATTATCAAACAAAGAAGTATTAGAAAGAGCAACAGATCATGCAAGAAGAG4381         
TCCATGTTTGAATTTTCTTGACAGATGGGTTGCAGACAAGTCATGGGAAGGTCATACAAA4441          
CTCATCAGACAACGCAAAGAAAATTGATAGCACAGTTTCTGAACATGACA AAGCTCTGGT4501         
CATGAAGAACAATCTCACAAGCAGAGTTTTGGGTAGACCTCCTCCAATGTCATCATCAGC4561          
TACGAGCTCTGAGACTTCATCCACATCTCAGTCCTCAGTTTCTTCCCAGGAAGTTTCCTT4621          
GAGGAAGGAGGTTATTACAGAAATCCAA GTTACATGAGCCTGGCAAAATCTATCAAAGCT4681         
AAGCAGAGATGATCACGGTATTCTTCATCGTCTTCTTCCAAAACCTGGTTTGAGAAAAAA4741          
CAATCCATGTCTTACAACAGAGATGTAAATGTAAAGTGTTGTGTTTGTTCGGATCAATCT4801          
TGCAA CCAGTGGAGTGATCTATATCGACCGGTTCAAGTAACAAGGAGAACTATGTGGGAA4861         
AGAGGCTAAATTAAACATCGTTTCATCAAAGATTGTTGCAATGTTGTTGTTTGGCCACTT4921          
TGATTATTTAATAATTAACTTCGGATGCTTCTGAGACAATCTGTTCCTCC CATTTTTTGT4981         
CAATATGAAACGAAGAGCAATGCTTCATCTTTAGACATGAAAAGCCATTTAAATGACCAA5041          
ATAACATAGTTTATACCAAAGCTTCCTTATAAATTTTACCCGTTCTAAAAATTGCTCTTA5101          
CTATCAAAATCTAAAACTGAATTAAATT CAATTATCTTACTGTTACACAGTTTTCACTAA5161         
TCACTATTTTAATGTATAAACTATAAAAATAAATTAAATACTTACTAAATTTTTAGATTT5221          
AATCCATAAATTATATTACAGTTCAGAGATTTCATCCACATTTCAGTCCCCAGTCCCTTA5281          
CTCAT TAAATTTTCCTGAGGAAGGAGGTTATACAGAAAGTCAACTTACATGAGCCTTACT5341         
CAATCTATCAAAGCTAAGAAGAGATGTCAGGTTCTTCTTCATCTTTCTGTTCCACATCAC5401          
CATTTAAGTAGAAACAGTATATGTCTTACAACGGTGATGTGAATGTAAAG GGTTGTGCTG5461         
GTTCGGAGTAGACTGATCTATATCCACCAGTGCAAGGAACATGGAGGCATATGTGGGCTA5521          
AAAAAAACATCATTAACTGAATCTTTAAAGCACTTTCAACATCTTGTTGGTTCCATGAAA5581          
TACATAAATGGATTATAGGTTATTGAAG CCATTGTTGTATATGTTTCTTACTTATAAATT5641         
AGTTTGAAGACAGCAATGTTGTTGTTTGGCCACTTTGATTATTTAATAATTAACTTCTGA5701          
TCTTTCTGAGACAATATGTTCCTCTTATTTCTTGTCAATATGAAACCAAGAGCAAAGTTT5761          
CATCC TTAGACATGAAAGGCTTATTAAATGACCAAATAACATAGTTTAGACGAAAGCTTC5821         
CTAATAAAATTTATTCTCACTATCTAAATCTAAAACTGAATTCAATTCATCTATCTGATT5881          
ATTATATAGTTTTCATTTTTTGTTATTTTATTGAATGAGTAAAAAATTTA ATTAAATACT5941         
TACTATTTTTTTCATATAATCTTATAAATTATGTTACGTGTGGGACATCCACCTAATAAC6001          
CTATTAATTTAAATAGTAATATTTGAAAAATATTTTATTGACATTGTTTTAAATAAATTC6061          
ATAATTCTAAAAATAGCAATAACTTTTT GAAAACATCAGATTTATGTACACGCATAGGAC6121         
ACATACCTTTTTATTTACTTAAAGGAAAATGAACGAGTCTAAAGCTTCCACATGTTATCT6181          
GAGCAAAACATGGATTTTTCTAAATTAGATTCGTTTAAATCAGAACATATTAATGTGAGT6241          
TTCTT AAATTAGATTTTTAATATGTATATATACGTAAGAATACTTCTTATGTTTAAAAAA6301         
AAAAATAGAATACTTTATCTCTTTCCTAAATTTTTAAGCCAATATCAATCCATTTCTATA6361          
ATCCAAGATGAAGAAATCCCTTCAACTCTCGTTTACGTTCTTA ATTATC6410                    
MetLysLysSerLeuGlnLeuSerPheThrPheLeuIleIle                                
657075                                                                    
TCCATCATTCTCTCACAAGGTTTGTATTTACATCTTAATATATTGCAT 6458                     
SerIleIleLeuSerGln                                                        
80                                                                        
ATAGTAATTCCATAATAAATTGATTATACTAAACTTTGACTTTTAAAATATTGTAAACCC6518          
CCCATATAATAAATTTTATTTACTATATAAAACATAGCATTAAATTATCTCTTTGTGTAA65 78         
AATTCATAACTTTGCAGAAGGGAAGAAAATATAGAAAGTATGGTCAGAAATGTTTGCGTT6638          
AATATTGAAAGAATCAACCCTGAAGTATTTAACTGTTTTTTATACTTTATGCCATTTATA6698          
ATTTTTTTAATGTATGGGTTTATATATGATGAAGAGCTATT ATGATAAAATAATATTAAA6758         
TAGTTTCATTTTTATCATCTATTTACGAACATTTTGTCTTGCACATACAAATGATTTAAC6818          
CGACATTTTTCATAATATGGATGAACTATAGTTCTTACGTAAATTTATTTGATATTTTTA6878          
ACTAATTTTATATATTTTT ATGCTTTTCCAATACATACAGTAGTTGTTCTTAAAATATCA6938         
AAATTTTATACGTAATGTTTATTAATATGCACACAATTCTTAAAACCATATTTTTCACAA6998          
AATAAAAAATAAAGTGTGACCAAACGATATGCTCATTTTTTTTTATATACTGGCAAAATA70 58         
TATTTCTTTTTTTTTTTACTTATAACGTTTAAAATGAAATGTTATTAAACATTTTTTGCT7118          
GATAAATAAATTTTCTATTTCATAAAATCTATATATATTTTCTAACAATTAAAATTTGAA7178          
ATTTTAATATCTTACAGGAATGATGGCAGATGCGCAG AAAAAGAATTGTCCT7230                 
MetMetAlaAspAlaGlnLysLysAsnCysPro                                         
8590                                                                      
CGTAAAATTCCAATAAAAGGAAGCTATTGTGCTCCAACTAT ATGTTTG7278                     
ArgLysIleProIleLysGlySerTyrCysAlaProThrIleCysLeu                          
95100105110                                                               
GATAAGTGTAAGAAGCAACATGGAACTGTTGGTAGTT GTGCGGAAGAA7326                     
AspLysCysLysLysGlnHisGlyThrValGlySerCysAlaGluGlu                          
115120125                                                                 
AAAGGATTTTGTAACTGCGCTTGTAAGTAAGAGTTCTC ACTAAGTGT7373                      
LysGlyPheCysAsnCysAlaCysLys                                               
130135                                                                    
AATGAATCTAGTAATGTCCAACCAAAGTTTTATATTATTTCTTTTAACAATAAGTCTAAA7433          
TGTTTGTCTCAGATTTGTGGAT CTATTTATAATAAATATTAATATGAATGTTAAATAAAT7493         
ACAATTGTATAAAACAAGAGTGGACTATTAATAAAATATATGATCACAGTATTGTTAGAA7553          
GTAACCAATATTACGTGTAAAATCAAAAGCTTAAGACTAGTTAAAAATATAGAGATGAAA7613          
 TCACAACCAATATTTAAATGTTATATAATCAACTAACATGTAATTTTGTACACATTGTAA7673         
AAAAAAAAAAAAAAAAAAAAAGCAAGAGTTGATTAACAAACAAGAAAGTGTTAGAAAGAG7733          
CAACAGATCATGCAAGAGCAGTCTAGGTTTGAATTGGCTTGACAG ATGTGTTGCAGACAT7793         
GCCATGAGGAAGTCTTACAAACTCATCAGACAACACACAGAAAATTGATAGCATTGTTTC7853          
TGAACATGACAAAGCTCTGGTCATGAAGAAAAATTTCACAGCCAAAGTTTTTGGTAGACC7913          
TTCTCCAGCTACGAGTTTTGAG ACTTCATCCACATCTCAGTCTCCATTTCCATTCTCATG7973         
AAGTTTTCTTTAGGGAAGAGGTTATTACAGAAAGCCAAGTTACATGAACCTAACACAATC8033          
TATCAAAGGTAAGAAGAGACGATCAACCAGTATTCTTCATCTTCTTGTTCCGAAATCACT8093          
 GTTTGAAAAGAAACAGTCAATGTCTTACAACGAAGATGTGAATGTAAAGTGTTGTGCATG8153         
TTCGGATCCATCTTGCACCCAGTGGAATGATCTATATCTACATGCTCAAGTAACAAGGAG8213          
AAATATGTGGGCAAAGAAGCTAAAGTAAACATTGTTTCATTAAAT CTTTAAAGCATTTCA8273         
ACACCTTGAGAGTTCTAAAACACACACAAAATACCGATTTATAGATATATAAGCAACTTC8333          
TATGTATGTTCTTTTACATACGAGTTAGTATGAAGACTGCTGCAATGTTGTTGTTTGACC8393          
ATTTTTATTATTTAATAGTTAA CTTCTGATGCTTCTAAAATAATATGTTCTTCCCAACTC8453         
TTGTCAATATGAAACCAAGAGCAAAGTTTTAATTTTAGACATGAAACGCCTATTAAATGA8513          
CCAAATAACATAGTTTAGACGAAAACTTCCTAATAAAATTTATTCTCACTATCTAAATCT8573          
 AAAACTGAATTC8585                                                         
(2) INFORMATION FOR SEQ ID NO:4:                                          
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 135 amino acids                                               
(B) TYPE: amino acid                                                      
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: protein                                               
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:                                   
MetLysLysSer LeuGlnLeuSerPheSerPheLeuIleIleSerIle                         
151015                                                                    
IleLeuSerHisGlyMetMetAlaAspAlaGlnLysLysAsnCysPro                          
20 2530                                                                   
HisLysIleProIleLysGlySerTyrCysAlaProThrIleCysLeu                          
354045                                                                    
AspMetCysLysLysGlnHisGlyThrValGlySe rCysAlaGluMet                         
505560                                                                    
LysLysSerLeuGlnLeuSerPheThrPheLeuIleIleSerIleIle                          
65707580                                                                  
 LeuSerGlnMetMetAlaAspAlaGlnLysLysAsnCysProArgLys                         
859095                                                                    
IleProIleLysGlySerTyrCysAlaProThrIleCysLeuAspLys                          
 100105110                                                                
CysLysLysGlnHisGlyThrValGlySerCysAlaGluGluLysGly                          
115120125                                                                 
PheCysAsnCysAlaCysLys                                                     
 130135                                                                   
(2) INFORMATION FOR SEQ ID NO:5:                                          
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 3641 base pairs                                               
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: double                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: DNA (genomic)                                         
(ix) FEATURE:                                                             
(A) NAME/KEY: CDS                                                         
(B) LOCATION: join(854..1105, 1266..2375, 2463..2779)                     
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:                                   
TTTTTTCCAAAACGAAACACATATGCGAGCCAGCNNCTATCACCCTCCGCCACGTGCACA60            
AGGATCAACTCCTTAAGCTCCTTATCTACGGACTCATCCTTAGTTATCTTAACCAAAATA120           
TTATTATAAAATTGCATAATCCATCGGTTTAGCTGCTAAGGAC TCCCAACGTGCCTCCGT180          
TGCATATGCTCTTATAAAACTTAACTTAAGTGCCGCCTAAACGGTCGTGTATACCATTTT240           
CTTTGGAGTTAAGTCACTATCTTCTTCATTTTCTTTCATCTATGTTTCTTTTGTTGGCCG300           
CGAATACAATGATGTGGCGG ACTCCCTTGCGAAGTCTGCTCTCCAGAACTATGTAGTAAA360          
CATTTTTCTTTTAGATTTATTATTCAGTTGGTTGACAAAAAAAAAGAGTGTTTAACCAAA420           
AAAACTAATAATAATAATAATAATAATAATAATAGTTCTGTAAATTTATCAGTTTGCATG480           
TGAACTTCTTGAAATACATTCAAGTTTATGTCTATAACTTATTCACGTGACTAATAGATT540           
TTTCTCTCTCAGAGTATTCTTTTAAAATCCAAAATAGCCAAATTCTCAAAGACATGGAAA600           
CCAAAGCCAAAAATTAGAAAAGGGAGAAAAATGTTAAGAGAAA CTAAAAACACTAATAAT660          
AGCGAGAGGTTAAACTTCAATGTTCCCAAATATGGAAATGAATAGCGAAATGAGAGGAGA720           
TGCCAAAGAAAATCAGAAAAAGCAGTCTTAAAAAACCCTATAAAAACGTCCTCAAGCATT780           
TTCACAACTCGAAATTCAAA CCCCGAAACATAACCAAATAAAAATAAAACATTAATACCC840          
CACAAAAACACATATGCGAGGGGTTAAACTATTGGCCGCGTGCCTCTAC889                      
MetArgGlyValLysLeuLeuAlaAlaCysLeuTyr                                      
 1510                                                                     
CTGGCCGCAGCCGCAACGGTGGTGGTCCATGCCGAAGACCCTTACTTC937                       
LeuAlaAlaAlaAlaThrValValValHisAlaGluAspProTyrPhe                          
15 2025                                                                   
CACCACGTATGGAACGTGACCTATGGAACCGCTTCTCCTCTAGGCGTT985                       
HisHisValTrpAsnValThrTyrGlyThrAlaSerProLeuGlyVal                          
30 3540                                                                   
CCACAACAAGTCATTCTAATCAACGGCCAATTCCCTGGTCCTAACATC1033                      
ProGlnGlnValIleLeuIleAsnGlyGlnPheProGlyProAsnIle                          
4550 5560                                                                 
AACTCAACCTCCAACAACAATGTCATCATCAACGTCTTCAACAACCTT1081                      
AsnSerThrSerAsnAsnAsnValIleIleAsnValPheAsnAsnLeu                          
65 7075                                                                   
GATGAACCCTTCCTCCTCACTTGGTAATATTAATAACCATTCATTCATCTACAA1135                
AspGluProPheLeuLeuThrTrp                                                  
80                                                                        
ACATATCTTTTCTCTAGAAAAAAAAAAGAACTCTTT AGCCATGGTCGAATCTAAAATTTA1195         
GAAAACATAAACATAAGGAGTCTGATCATTTACATTATTAATAAGTTATAATATATTTTT1255          
GCATTTTAGGAATGGAATCCAGCACAGGAAGAACTGTTGGCAAGATGGA1304                     
Asn GlyIleGlnHisArgLysAsnCysTrpGlnAspGly                                  
859095                                                                    
ACTCCGGGGACTATGTGTCCGATCATGCCCGGCACCAACTACACTTAC1352                      
ThrProGlyThrMet CysProIleMetProGlyThrAsnTyrThrTyr                         
100105110                                                                 
CATTTCCAGCCTAAAGATCAGATAGGAAGCTACTTCTACTATCCCACC1400                      
HisPheGlnProLysAspGln IleGlySerTyrPheTyrTyrProThr                         
115120125                                                                 
ACAGGGATGCACCGTGCCGCTGGTGGATATGGTGGACTCCGAGTGAAC1448                      
ThrGlyMetHisArgAlaAlaGlyGlyTy rGlyGlyLeuArgValAsn                         
130135140145                                                              
AGCCGTCTCCTCATCCCGGTCCCTTACGCTGATCCCGAAGATGACTAC1496                      
SerArgLeuLeuIleProValProT yrAlaAspProGluAspAspTyr                         
150155160                                                                 
ACTGTCCTCATCGGTGACTGGTACACTAAGAGCCACACCCAGTTGAAG1544                      
ThrValLeuIleGlyAspTrpTyr ThrLysSerHisThrGlnLeuLys                         
165170175                                                                 
AAGTTCCTCGACGGTGGTCGTACTATTGGTCGTCCAGACGGTATTGTC1592                      
LysPheLeuAspGlyGlyArgThrIle GlyArgProAspGlyIleVal                         
180185190                                                                 
ATCAACGGAAAGTCCGGAAAAGGTGATGGATCAGACGCACCGCTCTTC1640                      
IleAsnGlyLysSerGlyLysGlyAspGlySe rAspAlaProLeuPhe                         
195200205                                                                 
ACCTTGAAGCCTGGAAAGACTTACAGGGTTAGGATCTGTAACGTGGGT1688                      
ThrLeuLysProGlyLysThrTyrArgValArgIleCysA snValGly                         
210215220225                                                              
GTCAAGACATCTATCAACTTTAGGATTCAGAATCACAAGATGAAGCTC1736                      
ValLysThrSerIleAsnPheArgIleGlnAsnHis LysMetLysLeu                         
230235240                                                                 
GTTGAAATGGAAGGATCGCACGTTCTTCAAAACGATTACGACTCTCTT1784                      
ValGluMetGluGlySerHisValLeuGlnAsnAsp TyrAspSerLeu                         
245250255                                                                 
GACGTTCACGTTGGCCAGTGCTTTGGCACCATCGTTACCGCGAATCAA1832                      
AspValHisValGlyGlnCysPheGlyThrIleValTh rAlaAsnGln                         
260265270                                                                 
GAACCTAAAGATTACTACATGGTTGCATCCTCTAGGTTCTTGAAGACG1880                      
GluProLysAspTyrTyrMetValAlaSerSerArgPheLeuL ysThr                         
275280285                                                                 
GTTATCACAACAACCGGACTTCTCCGCTACGAGGGAGGCAAAGGACCC1928                      
ValIleThrThrThrGlyLeuLeuArgTyrGluGlyGlyLysGlyPro                          
290 295300305                                                             
GCCTCTTCACAGCTTCCGGCTGGTCCGGTCGGATGGGCCTGGTCGTTG1976                      
AlaSerSerGlnLeuProAlaGlyProValGlyTrpAlaTrpSerLeu                          
310315320                                                                 
AACCAGTTCCGATCCTTCAGGTGGAACTTGACCGCTAGTGCAGCTAGG2024                      
AsnGlnPheArgSerPheArgTrpAsnLeuThrAlaSerAlaAlaAr g                         
325330335                                                                 
CCTAACCCTCAGGGATCTTACCATTATGGAAAGATCAACATCACACGC2072                      
ProAsnProGlnGlySerTyrHisTyrGlyLysIleAsnIleThrArg                          
 340345350                                                                
ACAATCAAGCTCGTGAACACTCAAGGCAAGGTCGATGGTAAGCTTAGG2120                      
ThrIleLysLeuValAsnThrGlnGlyLysValAspGlyLysLeuArg                          
355 360365                                                                
TTTGCATTGAACGGAGTCTCCCACACAGAACCTGAGACCCCTCTGAAG2168                      
PheAlaLeuAsnGlyValSerHisThrGluProGluThrProLeuLys                          
370 375380385                                                             
CTGGCCGAATACTTTGGTATTTCCGACAAGGTGTTTAAGTATGATACC2216                      
LeuAlaGluTyrPheGlyIleSerAspLysValPheLysTyrAspThr                          
 390395400                                                                
ATCACCGATGACCCTACCCCGGAACAGATCAAAAACATCAAGATCGAG2264                      
IleThrAspAspProThrProGluGlnIleLysAsnIleLysIleGlu                          
 405410415                                                                
CCTAACGTTCTTAACATCACTCACCGTACCTTCGTCGAGGTGGTGTTT2312                      
ProAsnValLeuAsnIleThrHisArgThrPheValGluValValPhe                          
420 425430                                                                
GAGAACCACGAGAAGAGTGTTCAGTCTTGGCACTTGGATGGTTATTCT2360                      
GluAsnHisGluLysSerValGlnSerTrpHisLeuAspGlyTyrSer                          
435 440445                                                                
TTCTTCTCCGTTGCGTAAGTAAAACAAACACACACTTTGTTTCTTGCATCACAAG2415               
PhePheSerValAla                                                           
450                                                                       
TAACTCTTCATTTTAACCTAATTTTGACTTTTACTATCTTTTAAAGTGTTGAGCCA247 1             
ValGluPro                                                                 
455                                                                       
GGGACTTGGACCCCAGAGAAGAGGAAGAACTACAACCTCTTGGATGCA2519                      
 GlyThrTrpThrProGluLysArgLysAsnTyrAsnLeuLeuAspAla                         
460465470                                                                 
GTGAGCAGACACACAGTTCAAGTCTACCCAAAGTGCTGGGCAGCAATC2567                      
ValSer ArgHisThrValGlnValTyrProLysCysTrpAlaAlaIle                         
475480485                                                                 
TTGCTCACATTTGATAACTGTGGAATGTGGAACGTTCGTTCTGAGAAC2615                      
LeuLeuThrPheAs pAsnCysGlyMetTrpAsnValArgSerGluAsn                         
490495500505                                                              
ACAGAGAGACGTTACTTAGGACAGCAGTTTACGCCAGTGTCTTGTCTC2663                      
ThrGluArgA rgTyrLeuGlyGlnGlnPheThrProValSerCysLeu                         
510515520                                                                 
CAGAGAAATCACTTAGAGATGAATACAACATGCCTGAGACAAGCCTCC2711                      
GlnArgAsn HisLeuGluMetAsnThrThrCysLeuArgGlnAlaSer                         
525530535                                                                 
AATGTGGTCTCGTCAAAAACACACCTAAACCTGTTAACCCTTACGCTG2759                      
AsnValValSer SerLysThrHisLeuAsnLeuLeuThrLeuThrLeu                         
540545550                                                                 
GTGCCTAAGTTTAACTTTTAAATACAACTAAAGAGTTTTGATTCTTCTGTTGATC2814               
ValProLysPheAsnPh e                                                       
555                                                                       
TGAAAATTAATTTCTAAAATTATATGGTTTACTCGTATATACATGGAATTGAAAATGTAT2874          
GTATGTGTCTATACCTTTTAAGTAATTTTTCTTTCTTTCAAGAAGCATTAGTCTTCTCTT2934          
TGTTTTTTGTTCTTCACTTTTTTGTAACAATTAT GTAATGTATTATGTATCCATAATCTT2994         
CGATGAAATAAGCAAAAGAGATCTTATTTCTCCCAAAAAAAAAACTTTACAATAAAAGTA3054          
TTTCTCTATAGCCTAGAACCATGTATGATGATAACAAAACCCTTCTTCTTAGTCTGAGCC3114          
TTTTTCTAAGG CTCTTTATCTCGTGGTTCTTCCACCAACGGAGTTTCCTTGAGAGAGAAG3174         
TCATCGAGGCTATCATCATTCTCTGTATCGACCTGAACAAACTCTTTGAACATCGCCATT3234          
ACTTGAATCATAGTTGGTCTTTTGAACGGTCGATCGTCCAGACACTGAGACGCAATC TTC3294         
AAGTAATGAAACAGCTCAACGTCGCCAGATTTCTCAGTTATCAGGTCCGAATCAAGAATC3354          
TCAGCTCCTCTACTCTCCTTATAAAGCTGTTTAGCCCATCCCACGAGATTGTTGTCCTCA3414          
CCAAACTCCTCTGGATCGATCGGTTTCTTCCCCG AGAGAAGCTCCAGAAGTATAACCCCG3474         
TAGCTATACACATCTCCTTTGGTCGTGCACCTGAAACTCTGGTAATACTCTGGCGGAACG3534          
TAACCGGGAGTTCCCGCGAGCGTGTCACGCTCAAATGCGTGTCCAGAGCGCTCACCAGCC3594          
TTGCCATACCG AAGTCCGAGACGCGTGCTGTGAAGTCTTGGTCTAGA3641                      
(2) INFORMATION FOR SEQ ID NO:6:                                          
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 559 amino acids                                               
(B) TYPE: amino acid                                                      
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: protein                                               
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:                                   
MetArgGlyValLysLeuLeu AlaAlaCysLeuTyrLeuAlaAlaAla                         
151015                                                                    
AlaThrValValValHisAlaGluAspProTyrPheHisHisValTrp                          
2025 30                                                                   
AsnValThrTyrGlyThrAlaSerProLeuGlyValProGlnGlnVal                          
354045                                                                    
IleLeuIleAsnGlyGlnPheProGlyProAsnIleAsnSerThr Ser                         
505560                                                                    
AsnAsnAsnValIleIleAsnValPheAsnAsnLeuAspGluProPhe                          
65707580                                                                  
LeuLeuThrT rpAsnGlyIleGlnHisArgLysAsnCysTrpGlnAsp                         
859095                                                                    
GlyThrProGlyThrMetCysProIleMetProGlyThrAsnTyrThr                          
100 105110                                                                
TyrHisPheGlnProLysAspGlnIleGlySerTyrPheTyrTyrPro                          
115120125                                                                 
ThrThrGlyMetHisArgAlaAlaGlyGlyTyr GlyGlyLeuArgVal                         
130135140                                                                 
AsnSerArgLeuLeuIleProValProTyrAlaAspProGluAspAsp                          
145150155160                                                              
TyrThrValLeuIleGlyAspTrpTyrThrLysSerHisThrGlnLeu                          
165170175                                                                 
LysLysPheLeuAspGlyGlyArgThrIleGlyArgProAspGlyIle                          
 180185190                                                                
ValIleAsnGlyLysSerGlyLysGlyAspGlySerAspAlaProLeu                          
195200205                                                                 
PheThrLeuLysProGlyLysT hrTyrArgValArgIleCysAsnVal                         
210215220                                                                 
GlyValLysThrSerIleAsnPheArgIleGlnAsnHisLysMetLys                          
225230235 240                                                             
LeuValGluMetGluGlySerHisValLeuGlnAsnAspTyrAspSer                          
245250255                                                                 
LeuAspValHisValGlyGlnCysPheGlyThrIleValThr AlaAsn                         
260265270                                                                 
GlnGluProLysAspTyrTyrMetValAlaSerSerArgPheLeuLys                          
275280285                                                                 
ThrValIleTh rThrThrGlyLeuLeuArgTyrGluGlyGlyLysGly                         
290295300                                                                 
ProAlaSerSerGlnLeuProAlaGlyProValGlyTrpAlaTrpSer                          
305310 315320                                                             
LeuAsnGlnPheArgSerPheArgTrpAsnLeuThrAlaSerAlaAla                          
325330335                                                                 
ArgProAsnProGlnGlySerTyrHisTyrG lyLysIleAsnIleThr                         
340345350                                                                 
ArgThrIleLysLeuValAsnThrGlnGlyLysValAspGlyLysLeu                          
355360365                                                                 
 ArgPheAlaLeuAsnGlyValSerHisThrGluProGluThrProLeu                         
370375380                                                                 
LysLeuAlaGluTyrPheGlyIleSerAspLysValPheLysTyrAsp                          
385 390395400                                                             
ThrIleThrAspAspProThrProGluGlnIleLysAsnIleLysIle                          
405410415                                                                 
GluProAsnValLeuAsnIl eThrHisArgThrPheValGluValVal                         
420425430                                                                 
PheGluAsnHisGluLysSerValGlnSerTrpHisLeuAspGlyTyr                          
435440 445                                                                
SerPhePheSerValAlaValGluProGlyThrTrpThrProGluLys                          
450455460                                                                 
ArgLysAsnTyrAsnLeuLeuAspAlaValSerArgHisThrValGln                          
465 470475480                                                             
ValTyrProLysCysTrpAlaAlaIleLeuLeuThrPheAspAsnCys                          
485490495                                                                 
GlyMetTrp AsnValArgSerGluAsnThrGluArgArgTyrLeuGly                         
500505510                                                                 
GlnGlnPheThrProValSerCysLeuGlnArgAsnHisLeuGluMet                          
515 520525                                                                
AsnThrThrCysLeuArgGlnAlaSerAsnValValSerSerLysThr                          
530535540                                                                 
HisLeuAsnLeuLeuThrLeuThrLeuValProLysPheAs nPhe                            
545550555                                                                 
(2) INFORMATION FOR SEQ ID NO:7:                                          
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 4977 base pairs                                               
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: double                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: DNA (genomic)                                         
(ix) FEATURE:                                                             
(A) NAME/KEY: CDS                                                         
 (B) LOCATION: join(2158..3225, 3663..4046)                               
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:                                   
GGATCCGTTCCTTTCCGGTCATTTTCTCTCTCCGTCCATAGGAGAACATCCGATCATGAT60            
CACTCCGATCAAACTAGCCTTTCTCTTATTATTCATCACCACAACAGCAACCGCTGCACC120           
CAAAGCCAAACGCAGGAACTA CCTTTTCACACCGCATGCAAAAGCAGTCGCGGAATATGC180          
ACTGTTGTCCTAACAAACACAAGTCCATGCTGTAAAACCCTTAAACACGTTCCTACCGAT240           
GACCCTATCGAATTGATCCGAGCGTTAGCGGCTGCGACTGAATCTTCTGTGAAAAGAAGT300           
GTGGTTTTCCTCTCCGAGATCAAACCAAAACACAAATCAAACGCAACCGCAGCTGCAGTG360           
GTCAACAGCTGCGAAAAAAACTTGAAGTACGCATTAGAAGATTTCACTGATTTTTGGAAC420           
GCTATGGGGAAAGATGTAAAGACGTTGGCTCATAACTATTTCAC GTGTAAGAAGAAGTTA480          
ATGTCGATCATGGGGTACCATTGGACTTGTTTGGATGATATTGATGATAAGAATCTGTTG540           
AAGGAANTGGAGACTGGGATTAGTGTTGGGAAGAATCTAAGCAGTAATACGTATGATGTG600           
TTTAATGGTTTGAAAACTATT TTTAAGACGTTTGGTATCAAGGTGAAACTTAACGAGGAA660          
GACACTTCGCCCCAACCGCCACCATTGTCGAATTATTACTACTGATTAAATGATTTGGAT720           
GTAATAAATAATTAATATCACTCGTATAATGCCTAAAGCGACCATATATGTACGATGTAT780           
GTTCTAGGTTTTATACATGTACGGATGGATTTCGAGATGATTGGAAAGGATATATTAATG840           
GAATGTGAGTTTTTTTATAAGTTTTTGAATTGTCATCAAAATGAAGCTGAAAGTATATAT900           
GTTGATTACATAATTATTTGATAGACCTTGATAACTCGAACAAA TATACTATCGCAATCA960          
TTATTGGTTAAATGTTTTCGGATACATGTCCTACGTCAAACAAAATAATTGTGCATTTTT1020          
CATATATTTGATGCATGAAAGTTTCATATATTTGATGATGAAACCATGCATTTGTTTCCT1080          
TGTGCTCCCGGGACTTGTCAA CATTCAACGAACCTTCAGTAATCAACTACATATGATACT1140         
GATCTAGATGATGTATGTACATGTACGACCATGCATGAATCACGCCGATGTTTCTTTTAT1200          
CAAGGCGATGTTTAAAATGTACCCCGCTTTCTCGTTCTGGTAGGTATAAATACGAGTGAA1260          
ATAACATTCCTATGTATAGTATAGTAGTTCATTTTGTTGACCAAAATTTAAATATATAGG1320          
ACATAATTATATTTTCTCAAATGAATTTGAGTTTTGAGTGCCTCCTGAAAAGATGATTCC1380          
AGCTTTCAATTTTACAATGCTGGGTCAACCCCCCCAAGTATTAT CGTTATAAAAAAATAC1440         
TCAGAATAATCTCACACCTAAAACTGCGCATGAACTTGTTAATAGTCTAAAAAGATGTCC1500          
ATGAACTGAATGAATAATACCATTCATGTTTGAGTAACACCATAGATGACACAATTTTCT1560          
TACTACCACTAATAGATGACA CAATTGTCTTTGTTACATGTTGTAGTGTCCGATTAATTT1620         
GGGTTGAAGAAGATGAGAACTCTCGATGAGAAGCTTTAGAAACATGCATTTACTTTCGTT1680          
ACTTTCGAAATTCGGATGTAAAACTAGTACTAGGAATGAAAATCCCAAAATAAGTTGTTT1740          
ATTCTCTCTAATCCTAAAATTAATAAAATTATAATAGACTAACTTTTCCATCCTTAAGTT1800          
ACTTCTTATTTTTAGTAATCGAAGCTACACCTCTTGATCAGGACAAAGACATAATCAAAT1860          
CATCTTGTGGTGAATAATTTTTAATCTCAAATCCAATATTTGAT TAGAGAAGTTTCAGCC1920         
ATTCAACTACCTAAAATGTCTCCCTCCATGCAAAGCTCATGCGAACCTAATTTTAGAAAC1980          
TACAACTTCTATAAGAATCTCCCATAATGCACCATAATCTCCACCAGCCCCCATTAAATA2040          
ATCCACCGGGTCTGAATAAAT AAAAATAAGTCCCCTCCCTCTCCTATTTACCTCCTAAAT2100         
AAAACCTGAGGGAGAAAAAACAAAAAAAAAACAAAAAAATAGATTAAAAAATAAATA2157             
ATGGCGGTCGGGAAAATTGTGATATCAGTGGCATCCATGCTTCTAGTG2205                      
 MetAlaValGlyLysIleValIleSerValAlaSerMetLeuLeuVal                         
151015                                                                    
GTGGGTGTTGCCATAGGAGTTGTCACCTTTGTTAATAAAGGTGGTGGT2253                      
ValGlyValAlaIleGlyValValThrPheValAsnLysGlyGlyGly                          
202530                                                                    
GCAGGTGGCGACAAGACTCTGAACTCGCATCAGAAAGCGGTTGAGTCA2301                      
A laGlyGlyAspLysThrLeuAsnSerHisGlnLysAlaValGluSer                         
354045                                                                    
CTTTGTGCGTCAGCCACAGACAAAGGTTCATGCGCAAAAACACTTGAC2349                      
LeuCys AlaSerAlaThrAspLysGlySerCysAlaLysThrLeuAsp                         
505560                                                                    
CCAGTCAAAAGCGACGATCCAAGTAAACTTATCAAAGCCTTCATGTTA2397                      
ProValLysSerAsp AspProSerLysLeuIleLysAlaPheMetLeu                         
65707580                                                                  
GCTACAAAAGATGCTGTCACAAAATCCACAAACTTCACGGCTTCAACC2445                      
AlaThrLysAs pAlaValThrLysSerThrAsnPheThrAlaSerThr                         
859095                                                                    
GAAGAAGGTATGGGGAAAAACATTAACGCGACGAGCAAAGCCGTTCTT2493                      
GluGluGlyM etGlyLysAsnIleAsnAlaThrSerLysAlaValLeu                         
100105110                                                                 
GATTACTGCAAGAGAGTGCTGATGTACGCTCTCGAGGATCTTGAGACC2541                      
AspTyrCysLys ArgValLeuMetTyrAlaLeuGluAspLeuGluThr                         
115120125                                                                 
ATTGTTGAAGAAATGGGTGAAGATCTTCAGCAGAGTGGGAGTAAGATG2589                      
IleValGluGluMetGly GluAspLeuGlnGlnSerGlySerLysMet                         
130135140                                                                 
GACCAGCTTAAACAATGGTTAACCGGAGTTTTTAATTACCAAACCGAT2637                      
AspGlnLeuLysGlnTrpLeuThrGl yValPheAsnTyrGlnThrAsp                         
145150155160                                                              
TGTATTGATGATATTGAAGAATCGGAACTAAGAAAAGTCATGGGCGAA2685                      
CysIleAspAspIleGluGluS erGluLeuArgLysValMetGlyGlu                         
165170175                                                                 
GGAATCGCTCACTCCAAGATTTTGTCCAGTAACGCTATCGATATCTTC2733                      
GlyIleAlaHisSerLysIle LeuSerSerAsnAlaIleAspIlePhe                         
180185190                                                                 
CATGCTCTAACCACCGCAATGTCCCAAATGAATGTTAAGGTCGATGAC2781                      
HisAlaLeuThrThrAlaMetSer GlnMetAsnValLysValAspAsp                         
195200205                                                                 
ATGAAGAAAGGGAACCTCGGAGAAACTCCAGCTCCTGATCGTGATCTT2829                      
MetLysLysGlyAsnLeuGlyGluThrPr oAlaProAspArgAspLeu                         
210215220                                                                 
CTTGAAGACTTGGACCAAAAAGGATTACCTAAATGGCATTCTGACAAA2877                      
LeuGluAspLeuAspGlnLysGlyLeuProLysTrpH isSerAspLys                         
225230235240                                                              
GACAGGAAGCTTATGGCTCAGGCCGGACGCCCTGGTGCACCTGCTGAT2925                      
AspArgLysLeuMetAlaGlnAlaGlyArgPro GlyAlaProAlaAsp                         
245250255                                                                 
GAAGGTATCGGTGAAGGCGGCGGTGGTGGCGGTAAGATCAAGCCGACT2973                      
GluGlyIleGlyGluGlyGlyGlyGlyGlyGly LysIleLysProThr                         
260265270                                                                 
CATGTGGTGGCTAAGGACGGAAGTGGACAGTTTAAGACGATTTCTGAG3021                      
HisValValAlaLysAspGlySerGlyGlnPheLy sThrIleSerGlu                         
275280285                                                                 
GCGGTTAAAGCTTGTCCGGAGAAAAATCCTGGACGTTGCATTATCTAT3069                      
AlaValLysAlaCysProGluLysAsnProGlyArgCysI leIleTyr                         
290295300                                                                 
ATTAAGGCTGGTGTCTACAAGGAACAAGTCACTATCCCTAAGAAGGTA3117                      
IleLysAlaGlyValTyrLysGluGlnValThrIleProLysLysVal                          
 305310315320                                                             
AACAACGTTTTCATGTTTGGTGATGGTGCAACACAGACAATCATTACT3165                      
AsnAsnValPheMetPheGlyAspGlyAlaThrGlnThrIleIle Thr                         
325330335                                                                 
TTTGACAGAAGTGTTGGTCTTAGCCCTGGAACCACTACTTCACTCAGT3213                      
PheAspArgSerValGlyLeuSerProGlyThrThrThrSerLe uSer                         
340345350                                                                 
GGCACCGTTCGTAAGTCTCATTTAATTAATCTTGTCTTTAATTTTTCCTATC3265                  
GlyThrValArg                                                              
355                                                                       
TAAACTAAATTGCACCGTGCAATATCTA AATATACGTTGGTATCTAAATATACACATGCA3325         
CGTTGATATCTAATCATATACATGCATGCATGCAGAGGTTGAATCTGAGGGATTCATGGC3385          
GAAATGGATCGGGTTTCAGAACACTGCTGGTCCATTAGGACACCAAGCTGTCGCGTTCCG3445          
TGTGA ACGGAGACCGTGCGGTCATATTCAACTGCAGATTTGACGGTTACCAAGACACGCT3505         
CTACGTCAACAACGGACGTCAGTTCTACAGGAACATTGTTGTATCCGGTACAGTCGATTT3565          
CATCTTCGGAAAATCTGCGACCGTGATTCAAAACTCTCTAATCCTCTGCC GAAAGGGAAG3625         
CCCCGGACAAACCAACCACGTCACAGCCGACGGTAACGAGAAGGGTAAAGCGGTG3680               
GluLysGlyLysAlaVal                                                        
 360                                                                      
AAGATTGGTATCGTTCTCCATAACTGCCGTATCATGGCGGACAAAGAG3728                      
LysIleGlyIleValLeuHisAsnCysArgIleMetAlaAspLysGlu                          
365370 375                                                                
CTCGAAGCTGACAGGCTAACCGTCAAATCATACCTTGGACGGCCGTGG3776                      
LeuGluAlaAspArgLeuThrValLysSerTyrLeuGlyArgProTrp                          
380385390                                                                 
 AAACCATTTGCCACCACCGCAGTTATCGGAACTGAGATTGGCGATTTG3824                     
LysProPheAlaThrThrAlaValIleGlyThrGluIleGlyAspLeu                          
395400405 410                                                             
ATTCAACCGACAGGATGGAACGAATGGCAAGGAGAAAAATTCCATTTG3872                      
IleGlnProThrGlyTrpAsnGluTrpGlnGlyGluLysPheHisLeu                          
415420 425                                                                
ACAGCTACATATGTTGAGTTCAATAACCGTGGACCAGGAGCTAACACT3920                      
ThrAlaThrTyrValGluPheAsnAsnArgGlyProGlyAlaAsnThr                          
43043544 0                                                                
GCTGCGAGGGTTCCTTGGGCTAAGATGGCTAAGTCTGCTGCTGAGGTT3968                      
AlaAlaArgValProTrpAlaLysMetAlaLysSerAlaAlaGluVal                          
445450455                                                                 
GAA CGTTTCACCGTCGCTAACTGGTTGACTCCTGCTAACTGGATTCAA4016                     
GluArgPheThrValAlaAsnTrpLeuThrProAlaAsnTrpIleGln                          
460465470                                                                 
GAAGCCAACGT TCCTGTCCAGCTTGGATTATAAGAAAACTAACTAACAAA4066                   
GluAlaAsnValProValGlnLeuGlyLeu                                            
475480                                                                    
ATATATAACGAATAATATATAGTATGTGATCATGTAAAAAGGTAACGATACGACCTCGTC4126          
TCTCGGGATCAGGGCTCTTTTTGGTTATTATTAGGGTTCTAGGCGTTTTGGGATGATGTT4186          
TGTATAAGATTGCTTTTGTTTCACATGCAAAACATATATACAAAATATCTTATTTCTTCT4246          
TTTACTTTCTTTTATTCAAAATAATGAGTTTTTATAACCATGTT GATCTCTATATTATAG4306         
ACATCCTATCCCTAAACATGATAAATATAACTTCAAACTAATACCCTAGTAAAAATATAT4366          
AAACAAAAAAATACTTATGTAAGATTATGTGCAAGCATGGCTCAACAAATATAACTTTAT4426          
AAAAAGTTTGCATTATTGCTA TGTTTATATATGATTGCTATATGTAAGTATGTTGATAGA4486         
AGTTTATGAGGACAGAGATGACTATTGGCAAATATTAATGAGAAGTGTGATATGTTATCA4546          
TTTATCAAAACAAAGCAAGCCCTATATTACCAAATCAAATCTCACTTCAAAGCGAAGCTG4606          
CCCATTGATGATCTCACCAATATTTCACACATTACAAACGTGACATTATCTTCTCTTCTA4666          
TGGCTGTTTCCTTAACCAAAGTAAACAGAGTCCAAATCCAACCTTCCAAACCAACCCCAT4726          
TCATCTTATTGGGATCTGTCCTTGATCGATAACATTCCGGTTTT AAGATGTTTCGCAAGG4786         
ACAATACATCTCTTTACGCATGGACCTGATGCTGCTAGTAGAGTCATAAAAGATGCATCG4846          
GCTAAAGCAGTTGTCCCTTACTATCAATTGTTAAAGATCCTAAGGTGCTGCTATTGGATG4906          
AAGCAACAAGTTCCCTAGACG CCTAATCGGACTATGTGGTCCAAGATTCACTGGACCGGG4966         
TTATGGTTGAC4977                                                           
(2) INFORMATION FOR SEQ ID NO:8:                                          
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 484 amino acids                                               
(B) TYPE: amino acid                                                      
(D ) TOPOLOGY: linear                                                     
(ii) MOLECULE TYPE: protein                                               
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:                                   
MetAlaValGlyLysIleValIleSerValAlaSerMetLeuLeuVal                          
151015                                                                    
ValGlyValAlaIleGlyValValThrP heValAsnLysGlyGlyGly                         
202530                                                                    
AlaGlyGlyAspLysThrLeuAsnSerHisGlnLysAlaValGluSer                          
3540 45                                                                   
LeuCysAlaSerAlaThrAspLysGlySerCysAlaLysThrLeuAsp                          
505560                                                                    
ProValLysSerAspAspProSerLysLeuIleLysAlaPheMetLeu                          
65 707580                                                                 
AlaThrLysAspAlaValThrLysSerThrAsnPheThrAlaSerThr                          
859095                                                                    
GluGluGlyMetGlyLy sAsnIleAsnAlaThrSerLysAlaValLeu                         
100105110                                                                 
AspTyrCysLysArgValLeuMetTyrAlaLeuGluAspLeuGluThr                          
115120 125                                                                
IleValGluGluMetGlyGluAspLeuGlnGlnSerGlySerLysMet                          
130135140                                                                 
AspGlnLeuLysGlnTrpLeuThrGlyValPheAsnTyrGlnThrAsp                          
 145150155160                                                             
CysIleAspAspIleGluGluSerGluLeuArgLysValMetGlyGlu                          
165170175                                                                 
GlyIle AlaHisSerLysIleLeuSerSerAsnAlaIleAspIlePhe                         
180185190                                                                 
HisAlaLeuThrThrAlaMetSerGlnMetAsnValLysValAspAsp                          
195 200205                                                                
MetLysLysGlyAsnLeuGlyGluThrProAlaProAspArgAspLeu                          
210215220                                                                 
LeuGluAspLeuAspGlnLysGlyLeuProLysTrpHi sSerAspLys                         
225230235240                                                              
AspArgLysLeuMetAlaGlnAlaGlyArgProGlyAlaProAlaAsp                          
245250 255                                                                
GluGlyIleGlyGluGlyGlyGlyGlyGlyGlyLysIleLysProThr                          
260265270                                                                 
HisValValAlaLysAspGlySerGlyGlnPheLysThrIleSerGlu                          
 275280285                                                                
AlaValLysAlaCysProGluLysAsnProGlyArgCysIleIleTyr                          
290295300                                                                 
IleLysAlaGlyValTyrLysGluGln ValThrIleProLysLysVal                         
305310315320                                                              
AsnAsnValPheMetPheGlyAspGlyAlaThrGlnThrIleIleThr                          
325330 335                                                                
PheAspArgSerValGlyLeuSerProGlyThrThrThrSerLeuSer                          
340345350                                                                 
GlyThrValArgGluLysGlyLysAlaValLysIleGlyIl eValLeu                         
355360365                                                                 
HisAsnCysArgIleMetAlaAspLysGluLeuGluAlaAspArgLeu                          
370375380                                                                 
ThrValLysSerTyr LeuGlyArgProTrpLysProPheAlaThrThr                         
385390395400                                                              
AlaValIleGlyThrGluIleGlyAspLeuIleGlnProThrGlyTrp                          
405 410415                                                                
AsnGluTrpGlnGlyGluLysPheHisLeuThrAlaThrTyrValGlu                          
420425430                                                                 
PheAsnAsnArgGlyProGlyAlaAsnThr AlaAlaArgValProTrp                         
435440445                                                                 
AlaLysMetAlaLysSerAlaAlaGluValGluArgPheThrValAla                          
450455460                                                                 
AsnT rpLeuThrProAlaAsnTrpIleGlnGluAlaAsnValProVal                         
465470475480                                                              
GlnLeuGlyLeu                                                              
(2) INFORMATION FOR SEQ ID NO:9:                                          
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 12 base pairs                                                 
(B) TYPE: nucleic acid                                                    
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: DNA (genomic)                                         
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:                                   
TATGTTTTAAAA12                                                            
(2) INFORMATION FOR SEQ ID NO:10:                                         
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH: 11 base pairs                                                 
( B) TYPE: nucleic acid                                                   
(C) STRANDEDNESS: single                                                  
(D) TOPOLOGY: linear                                                      
(ii) MOLECULE TYPE: DNA (genomic)                                         
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:                                  
TATGTTTAAAA11